INSULIN-INCRETIN CONJUGATES

BACKGROUND OF THE INVENTION
(1) Field of the Invention

The present invention relates to insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes.

(2) Description of Related Art

Insulin is an essential therapy for type 1 diabetes mellitus (T1DM) patients and many type 2 mellitus diabetics (T2DMs), prescribed to close to one third of U.S. patients among all anti-diabetic drug users in the past decade. The worldwide market for insulins is growing at a faster rate than all other anti-diabetic agents combined and is expected to reach US$32.24 billion by 2019. Type 2 diabetes mellitus (T2DM) in particular is a growing global public health problem. However, challenges of current insulin therapies, including narrow therapeutic index (TI) to hypoglycemia and body weight gain, limit their wider adoption and potential for patients to achieve ideal glycemic control, particularly for patients with T2DM.

Due to the progressive nature of diabetes, a combination(s) of two or more drugs acting on different pathophysiological processes is often necessary to achieve an early and sustained achievement of individualized glycemic targets. However, in choosing a therapy it is important that the treatment avoids hypoglycemia. Incretins are a relatively recent class of anti-diabetic drugs and have been shown to have efficacy with an acceptable safety profile. Attempts have been made to combine various incretins with a basal insulin for management of T2DM. Currently, exenatide/long acting exenatide and liraglutide have been co-administered with basal insulin like glargine and detemir, respectively. Currently, a fixed-dose or fixed-ratio combination of insulin degludec and liraglutide is under development. Fixed-dose or fixed-ratio combination or by co-administration may improve control of fasting and postprandial glucose.

Incretins are a group of gastrointestinal hormones that that are involved in a wide variety of physiological functions, including glucose homeostasis, insulin secretion, gastric emptying, and intestinal growth, as well as the regulation of food intake. Pre-proglucagon is a 158 amino acid precursor peptide that is processed in different tissues to form a number of different peptides. Incretins include a number of proglucagon-derived peptides, including glucagon (GCG), glucagon-like peptide-1 (GLP-1; amino acids 7-36 and amino acids 7-35, glucagon-like peptide-2 (GLP-2) and oxyntomodulin (OXM).

GCG is a 29-amino acid peptide that corresponds to amino acids 33 through 61 of pre-proglucagon, while GLP-1 is produced as a 37-amino acid peptide that corresponds to amino acids 72 through 108 of pre-proglucagon. GLP-1(7-36) C-terminal amide and GLP-1(7-37) acid are biologically potent forms of GLP-1 that demonstrate essentially equivalent activity at the GLP-1 receptor.

GCG is a life-saving medicine that is used in the acute treatment of severe hypoglycemia. Oxyntomodulin (OXM) has been reported to have pharmacological ability to suppress appetite and lower body weight. Clinical studies with GLP-1 receptor agonists or stabilized GLP-1 analogs have proven this family of peptides to be an effective treatment for T2DM.

Gastric inhibitory peptide or glucose-dependent insulinotropic peptide (GIP) is a member of the secretin family of hormones. GIP is derived from a 153-amino acid proprotein encoded by the GIP gene and circulates as a biologically active 42-amino acid peptide. The GIP gene is expressed in the small intestine as well as the salivary glands and is a weak inhibitor of gastric acid secretion. In addition to its inhibitory effects in the stomach, in the presence of glucose, GIP enhances insulin release by pancreatic beta islet cells when administered in physiological doses. GIP is believed to function as an enteric factor that stimulates the release of pancreatic insulin and that may play a physiological role in maintaining glucose homeostasis.

GCG-related peptide analogs and derivatives modified to have various degrees of activity at the GLP-1 receptor, the GIP receptor, and the GCG receptor have been disclosed in Published International Application Nos. WO2008/1010017, WO2009/155258, WO2011/075393, WO2012/177444, and WO2012/177443. Two independent and simultaneous papers reported the use of relatively balanced GLP-1 receptor/GCG receptor co-agonists as being of enhanced efficacy and safety relative to pure GLP1R agonists in the treatment of rodent obesity, with simultaneous improvement in glycemic control (Day et al., Nat. Chem. Biol. 5: 749-757 (2009); Pocai eta al., Diabetes 58: 2258-2266 (2009)).

While fixed-dose or fixed-ratio combination or by co-administration may lead to improved control over fasting and postprandial glucose, neither method is without limitations, e.g., pH solubility/stability incompatibility and/or limited ability to adjust the ratio between two molecules having different pharmacologies.

An improvement to simultaneous administration of insulin and an incretin to control T2DM was disclosed in WO2014158900, which disclosed conjugates formed between an insulin molecule and an incretin, including for example a GCG-related peptide, wherein the conjugate has agonist activity at both the insulin receptor and the corresponding incretin receptor(s).

BRIEF SUMMARY OF THE INVENTION

The present invention provides insulin-incretin conjugates formed between an insulin molecule and an incretin, including for example a GCG-related peptide, wherein the conjugate has agonist activity at both the insulin receptor and the corresponding incretin receptor(s). The conjugation of a GCG-related peptide (e.g., a peptide having agonist activity at the GIP receptor, the GLP-1 receptor, the GCG receptor or combinations thereof) is anticipated to produce a beneficial therapeutic addition to the insulin molecule activity.

The present invention provides a compound comprising an insulin molecule having agonist activity at the insulin receptor conjugated via a non-peptide linking moiety to a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor, wherein the non-peptide linking moiety comprises a 1,4-disubstituted 1, 2, 3-triazole.

In particular embodiments, the peptide comprises (a) a first linker arm having a proximal end linked to an amino acid of the peptide and a distal end linked to an azide group and the insulin molecule comprises a second linker arm having a proximal end linked to an amino acid of the insulin molecule and a distal end linked to an alkyne group, wherein the azide group and the alkyne group form the 1,4-disubstituted 1,2,3-triazole; or (b) a first linker arm having a proximal end linked to an amino acid of the peptide and a distal end linked to an alkyne group and the insulin molecule comprises a second linker arm having a proximal end linked to an amino acid of the insulin molecule and a distal end linked to an azide group, wherein the azide group and the alkyne group form the 1,4-disubstituted 1,2,3-triazole in either case.

In particular embodiments, the peptide comprises within its amino acid sequence (a) an azido-norleucine and the insulin molecule comprises a linker arm having a proximal end linked to the amino group of an amino acid of the insulin molecule and a distal end linked to an alkynyl group, wherein the azido group and the alkynyl group form the 1,4-disubstituted 1,2,3-triazole; or (b) an alkynyl-norleucine and the insulin molecule comprises a linker arm having a proximal end linked to the amino group of an amino acid of the insulin molecule and a distal end linked to an azido group, wherein the azido group and the alkynyl group form the 1,4-disubstituted 1,2,3-triazole; or (c) a propargyl-Glycine and the insulin molecule comprises a linker arm having a proximal end linked to the amino group of an amino acid of the insulin molecule and a distal end linked to an azido group, wherein the azido group and the alkynyl group form the 1,4-disubstituted 1,2,3-triazole.

In particular embodiments, the insulin molecule comprises within its amino acid sequence (a) an azido-norleucine and the peptide comprises a linker arm having a proximal end linked to the amino group of an amino acid of the peptide and a distal end linked to an alkynyl group, wherein the azido group and the alkynyl group form the 1,4-disubstituted 1,2,3-triazole; or (b) an alkynyl-norleucine and the peptide comprises a linker arm having a proximal end linked to the amino group of an amino acid of the peptide and a distal end linked to an azido group, wherein the azido group and the alkynyl group form the 1,4-disubstituted 1,2,3-triazole; or (c) a propargyl-Glycine and the insulin molecule comprises a linker arm having a proximal end linked to the amino group of an amino acid of the insulin molecule and a distal end linked to an azido group, wherein the azido group and the alkynyl group form the 1,4-disubstituted 1,2,3-triazole.

In particular embodiments, the insulin molecule comprises an A-chain peptide and a B-chain peptide.

In particular embodiments, the insulin molecule is a heterodimer molecule or a single-chain insulin molecule.

In particular embodiments, the insulin molecule is selected from the group consisting of human insulin, insulin lispro, insulin detemir, insulin glulisine, and insulin glargine.

In particular embodiments, the insulin molecule is conjugated to the peptide via the N-terminal amino acid of the A-chain peptide, the N-terminal amino acid of the B-chain peptide, or the amino acid at position 28 or 29 of the B-chain peptide.

In particular embodiments, the peptide is conjugated to the insulin molecule via an amino acid at position 20, 21, 24, 30, or 31 of the peptide.

In particular embodiments, the peptide is also conjugated to a fatty acid or fatty diacid. In further embodiments, the fatty acid or fatty diacid is conjugated to the epsilon amine of a lysine residue at amino acid position 10 or 20 of the peptide.

In particular embodiments, the conjugate comprises the formula

embedded image

wherein R₁and R₂independently comprise a C₁-C₅₀hydrocarbon chain or substituted hydrocarbon chain, a PEG_nwherein n is 1-50, a (PEG₂)_nwherein n is 1-50, a (PEG₂)_n-(γGlu)_p-C_nwherein each n is independently 1-50 and p is 1 or 2, a (PEG₂)_n-C_nwherein each n is independently is 1-50, a (PEG)_n(PEG)_nwherein each n is independently 1-50, a PEG_n-(Lys-(γGlu)_p-C_n)—C_nwherein each n is independently 1-50 and p is 1 or 2, and a C₅-Lys(γE-C_n)-PEG_nwherein each n is independently 1-50, and wherein the bond between the linking moiety and the insulin molecule and the incretin peptide are indicated by the wavy lines with the proviso that if the bond adjacent to R₁is to insulin then the bond adjacent to R₂is to the incretin peptide or that if the bond adjacent to R₁is to the incretin peptide then the bond adjacent to R₂is to insulin.

In particular embodiments, the incretin peptide is a glucagon derived that comprises the amino acid sequence

(SEQ ID NO: 1)

HSQGTFTSDYSKYLDERAAQDFVQWLLDT

which further includes at least the following modifications: (i) a substitution of the amino acid at position 2 with an amino acid that renders the peptide resistant to cleavage and inactivation by dipeptidyl peptidase IV; (ii) a lipid moiety covalently linked to the peptide at a lysine residue substituted for the tyrosine residue at position 10 or the glutamine at position 20 of the peptide; (iii) an azide group or an alkyne group conjugated to an amino acid at position 20, 21, 24, 30, or 31; (iv) 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional amino acid substitutions in addition to the substitution at position 2; and optionally, a protecting group that is joined to the C-terminal carboxy group and/or the N-terminal amino group. In embodiments in which the modified glucagon peptide has agonist activity at the GIP receptor, the Histidine at position 1 is substituted with Tyrosine, Phenylalanine, Tryptophan, or other amino acid with an aromatic group.

In particular embodiments, the peptide comprises a substitution of the Ser at position 2 with Val, Ile, Asp, Glu, Met, Trp, Asn, D-Ala, D-Ser, α-methyl-Ser, α-methyl-D-Ser or α-aminoisobutyric acid (aib or U). In particular embodiments, the Ser is substituted with D-Ser or aib. These substitutions at position 2 render the peptide resistant to DPP-4 and active at the GLP-1 receptor. Peptides with a substitution are co-agonists of the GCG and the GLP-1 receptors.

In particular embodiments, the Gln at position 3 is substituted with Glu or Asp. These substitutions increase the selectivity of the peptide for the GLP-1 receptor over the GCG receptor. Such peptides have little or no activity at the GCG receptor.

In particular embodiments, the peptide includes a substitution of the Glu at position 16 with aib, Asn, Ser, or Ala.

In particular embodiments the His at position 1 is substituted with an amino acid with a large aromatic group, for example, Tyr, Phe, or Trp. When this substitution includes the substitution of the Ser at position 2 with aib or D-Ser, the substitution of the Lys at position 12 with Ile and substitution of the Glu at position 16 with aib, the peptide has agonist activity at the GCG, GLP-1 and GIP receptors. When the peptide further includes a substitution of the Gln at position 3 with Glu or Asp, the peptide has agonist activity at the GLP-1 and GIP receptors.

In particular embodiments, the compound comprises a peptide selected from the group consisting of peptides shown in Table 1, e.g., a group of peptides consisting of PEP1, PEP2, PEP3, PEP4, PEP5, PEP6, PEP7, PEP8, PEP9, PEP10, PEP11, PEP12, PEP13, PEP14, PEP15, PEP16, PEP17, PEP18, PEP19, PEP20, PEP21, PEP22, PEP23, PEP24, PEP25, PEP26, PEP27, PEP28, PEP29, PEP30, PEP31, PEP32, PEP33, PEP34, PEP35, PEP36, PEP37, PEP38, PEP39, PEP40, PEP41, PEP42, PEP43, PEP44, PEP45, PEP46, PEP47, PEP48, PEP49, PEP50, PEP51, PEP52, PEP53, PEP54, PEP55, PEP56, PEP57, PEP58, PEP59, PEP60, PEP61, PEP62, PEP63, PEP64, PEP65, PEP66, PEP67, PEP68, PEP69, PEP70, PEP71, PEP72, PEP73, PEP74, PEP75, PEP76, PEP77, PEP78, PEP79, PEP80, PEP81, PEP82, PEP83, PEP84, PEP85, PEP86, PEP87, PEP88, PEP89, PEP90, PEP91, PEP92, PEP93, PEP94, PEP95, PEP96, PEP97, PEP98, PEP99, PEP100, PEP101, PEP102, PEP103, PEP104, PEP105, PEP106, PEP107, PEP108, PEP109, PEP110, PEP111, PEP112, PEP113, PEP114, PEP115, PEP116, PEP117, PEP118, PEP119, PEP120, PEP121, PEP122, PEP123, PEP124, PEP125, PEP126, PEP127, PEP128, PEP129, PEP130, PEP131, and PEP132.

The present invention further provides a conjugate comprising an insulin analog selected from the group consisting of INS1, INS2, INS3, INS4, INS5, INS6, INS7, INS8, INS9, INS10, INS11, INS12, INS13, INS14, INS15, INS16, INS17, INS18, INS19, INS20, INS21, INS22, INS23, INS24, INS25, INS26, INS27, INS28, INS29, INS30, and INS31 conjugated to a peptide selected from the group consisting of PEP1, PEP2, PEP3, PEP4, PEP5, PEP6, PEP7, PEP8, PEP9, PEP10, PEP11, PEP12, PEP13, PEP14, PEP15, PEP16, PEP17, PEP18, PEP19, PEP20, PEP21, PEP22, PEP23, PEP24, PEP25, PEP26, PEP27, PEP28, PEP29, PEP30, PEP31, PEP32, PEP33, PEP34, PEP35, PEP36, PEP37, PEP38, PEP39, PEP40, PEP41, PEP42, PEP43, PEP44, PEP45, PEP46, PEP47, PEP48, PEP49, PEP50, PEP51, PEP52, PEP53, PEP54, PEP55, PEP56, PEP57, PEP58, PEP59, PEP60, PEP61, PEP62, PEP63, PEP64, PEP65, PEP66, PEP67, PEP68, PEP69, PEP70, PEP71, PEP72, PEP73, PEP74, PEP75, PEP76, PEP77, PEP78, PEP79, PEP80, PEP81, PEP82, PEP83, PEP84, PEP85, PEP86, PEP87, PEP88, PEP89, PEP90, PEP91, PEP92, PEP93, PEP94, PEP95, PEP96, PEP97, PEP98, PEP99, PEP100, PEP101, PEP102, PEP103, PEP104, PEP105, PEP106, PEP107, PEP108, PEP109, PEP110, PEP111, PEP112, PEP113, PEP114, PEP115, PEP116, PEP117, PEP118, PEP119, PEP120, PEP121, PEP122, PEP123, PEP124, PEP125, PEP126, PEP127, PEP128, PEP129, PEP130, PEP131, and PEP132.

The present invention further provides a conjugate selected from group of conjugates shown in Table 4, e.g., a conjugate selected from the group consisting of CON1, CON2, CON3, CON4, CON5, CON6, CON7, CON8, CON9, CON10, CON11, CON12, CON13, CON14, CON15, CON16, CON17, CON19, CON20, CON21, CON22, CON23, CON24, CON25, CON26, CON27, CON28, CON29, CON30, CON31, CON32, CON33, CON34, CON35, CON36, CON37, CON38, CON39, CON40, CON41, CON42, CON43, CON44, CON45, CON46, CON47, CON48, CON49, CON50, CON51, CON52, CON53, CON55, CON56, CON57, CON58, CON59, CON60, CON61, CON62, CON63, CON64, CON65, CON66, CON67, CON68, CON69, CON70, CON71, CON72, CON73, CON74, CON75, CON76, CON77, CON78, CON79, CON80, CON81, CON82, CON83, CON84, CON85, CON86, CON87, CON88, CON89, CON90, CON91, CON92, CON93, CON94, CON95, CON96, CON97, CON98, CON99, CON101, CON102, CON103, CON104, CON105, CON106, CON107, CON108, CON109, CON110, CON111, CON112, CON113, CON114, CON115, CON116, CON117, CON118, CON119, CON120, CON121, CON122, CON123, CON124, CON125, CON126, CON127, CON128, CON129, CON130, CON131, CON132, CON133, CON134, CON135, CON136, CON137, CON138, CON139, CON140, CON141, CON142, CON143, CON144, CON145, CON146, CON147, CON148, CON149, CON150, CON151, CON152, CON153, CON154, CON155, CON156, CON157, CON158, CON159, CON160, and CON161.

The present invention further provides pharmaceutical formulation comprising a compound of the above and a pharmaceutically acceptable carrier.

The present invention further provides for the use of a compound of the above in a treatment for a metabolic disease.

The present invention further provides for the use of a compound of the above for the manufacture of a medicament for the treatment of a metabolic disease.

The present invention further provides a method for treating a metabolic disease, comprising administering to an individual in need an effective amount of a compound of any one of the preceding claims to treat the metabolic disease. In particular embodiments, the metabolic disease is diabetes.

Definitions

The term “about” as used herein means greater or lesser than the value or range of values stated by 10 percent, but is not intended to designate any value or range of values to only this broader definition. Each value or range of values preceded by the term “about” is also intended to encompass the embodiment of the stated absolute value or range of values.

As used herein, the term “pharmaceutically acceptable carrier” includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents. The term also encompasses any of the agents approved by a regulatory agency of the U.S. Federal government or listed in the U.S. Pharmacopeia for use in animals, including humans.

As used herein the term “pharmaceutically acceptable salt” refers to salts of compounds that retain the biological activity of the parent compound, and which are not biologically or otherwise undesirable. Many of the compounds disclosed herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.

Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases, include by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines.

As used herein, the term “treating” includes prophylaxis of the specific disorder or condition, or alleviation of the symptoms associated with a specific disorder or condition and/or preventing or eliminating said symptoms. For example, as used herein the term “treating diabetes” will refer in general to altering glucose blood levels in the direction of normal levels and may include increasing or decreasing blood glucose levels depending on a given situation.

As used herein an “effective” amount or a “therapeutically effective amount” of a glucagon peptide refers to a nontoxic but sufficient amount of the peptide to provide the desired effect or a meaningful patient benefit. For example one desired effect would be the prevention or treatment of hyperglycemia, e.g., as measured by a change in blood glucose level closer to normal, or inducing weight loss/preventing weight gain, e.g., as measured by reduction in body weight, or preventing or reducing an increase in body weight, or normalizing body fat distribution. The amount that is “effective” will vary from subject to subject, depending on the age and general condition of the individual, mode of administration, and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.

The term, “parenteral” means not through the alimentary canal but by some other route, e.g., subcutaneous, intramuscular, intraspinal, or intravenous.

As used herein, the term “peptide” encompasses a chain of 11 or more amino acids and typically less than 50 amino acids, wherein the amino acids are naturally occurring or coded or non-naturally occurring or non-coded amino acids. Non-naturally occurring amino acids refer to amino acids that do not naturally occur in vivo but which, nevertheless, can be incorporated into the peptide structures described herein. “Non-coded” as used herein refers to an amino acid that is not an L-isomer of any of the following 20 amino acids: Ala, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr. “Coded” as used herein refers to an amino acid that is an L-isomer of any of the following 20 amino acids: Ala, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr. In some embodiments, the peptides and variant peptides described herein are about the same length as SEQ ID NO: 1 (which is 29 amino acids in length), e.g. 25-35 amino acids in length. Exemplary lengths include 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length. The term further includes peptides wherein one or more amino acids is conjugated to a second molecule via a linker.

Amino acid “modification” refers to an insertion, deletion or substitution of one amino acid with another. In some embodiments, the amino acid substitution or replacement is a conservative amino acid substitution, e.g., a conservative substitution of the amino acid at one or more of positions 2, 5, 7, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 24, 27, 28 or 29. As used herein, the term “conservative amino acid substitution” is the replacement of one amino acid with another amino acid having similar properties, e.g., size, charge, hydrophobicity, hydrophilicity, and/or aromaticity, and includes exchanges within one of the following five groups:

I. Small aliphatic, nonpolar or slightly polar residues:

Ala, Ser, Thr, Pro, Gly;

II. Polar, negative-charged residues and their amides and esters:

Asp, Asn, Glu, Gln, cysteic acid and homocysteic acid;

III. Polar, positive-charged residues:

His, Arg, Lys; Omithine (Orn)

IV. Large, aliphatic, nonpolar residues:

Met, Leu, Ile, Val, Cys, Norleucine (Nle), homocysteine

V. Large, aromatic residues:

Phe, Tyr, Trp, acetyl phenylalanine

In some embodiments, the amino acid substitution is not a conservative amino acid substitution, e.g., is a non-conservative amino acid substitution.

As used herein the term “charged amino acid” or “charged residue” refers to an amino acid that comprises a side chain that is negative-charged (i.e., de-protonated) or positive-charged (i.e., protonated) in aqueous solution at physiological pH. For example negative-charged amino acids include aspartic acid, glutamic acid, cysteic acid, homocysteic acid, and homoglutamic acid, whereas positive-charged amino acids include arginine, lysine and histidine. Charged amino acids include the charged amino acids among the 20 coded amino acids, as well as atypical or non-naturally occurring or non-coded amino acids.

As used herein the term “acidic amino acid” refers to an amino acid that comprises a second acidic moiety (other than the carboxylic acid of the amino acid), including for example, a carboxylic acid or sulfonic acid group.

As used herein, the term “acylated amino acid” refers to an amino acid comprising an acyl group which is non-native to a naturally-occurring amino acid, regardless of the means by which it is produced (e.g. acylation prior to incorporating the amino acid into a peptide, or acylation after incorporation into a peptide).

As used herein the term “alkylated amino acid” refers to an amino acid comprising an alkyl group which is non-native to a naturally-occurring amino acid, regardless of the means by which it is produced. Accordingly, the acylated amino acids and alkylated amino acids of the present disclosures are non-coded amino acids.

As used herein, the term “selectivity” of a molecule for a first receptor relative to a second receptor refers to the following ratio: EC₅₀of the molecule at the second receptor divided by the EC₅₀of the molecule at the first receptor. For example, a molecule that has an EC50 of 1 nM at a first receptor and an EC₅₀of 100 nM at a second receptor has 100-fold selectivity for the first receptor relative to the second receptor.

As used herein, “glucagon potency” or “potency compared to native glucagon” of a molecule refers to the inverse ratio of the EC₅₀of the molecule at the glucagon receptor divided by the EC₅₀of native glucagon at glucagon receptor.

As used herein, “GLP-1 potency” or “potency compared to native GLP-1” of a molecule refers to the inverse ratio of the EC₅₀of the molecule at GLP-1 receptor divided by the EC₅₀of native GLP-1 at GLP-1 receptor.

As used herein, “PEG” refers to a polyethylene glycol molecule and “PEG_n” refers to a polyethylene glycol molecule have n number of ethylene groups.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows a 3D schematic representation of an insulin-incretin conjugate in which a 1,4-disubstituted 1, 2, 3,-triazole linking moiety links the B1 amino acid to an Nle amino acid in an incretin peptide.

FIG. 1B shows in the upper panel a schematic representation of a Cu(I)-catalyzed Azide-Alkyne Cycloaddition (CuAAC) process that may be used to construct the insulin-incretin conjugates disclosed herein and in the lower panel a Cu-free AAC process that may be used to construct insulin-incretin conjugates wherein one linker comprises a terminal azide and the other linker comprises a strained cyclooctyne.

FIG. 2A, FIG. 2B, and FIG. 2C show various exemplary insulin-incretin conjugates in which the Norleucine (Nle) amino acid of particular incretins is conjugated to the epsilon amino group of Lysine (Lys) at position B29 of the B-chain peptide. The “*” indicates that the incretin has the amino acid sequence and structure of the indicated incretin but wherein the azide group of the linker has formed a 1,2-disubstituted 1,2,3-triazole with the alkyne group on the insulin.

FIG. 3 shows various exemplary insulin-incretin conjugates in which the Nle amino acid of particular incretins is conjugated to the amino group of the Glycine (Gly) at position A1 of the A-chain peptide. The “*” indicates that the incretin has the amino acid sequence and structure of the indicated incretin but wherein the azide group of the linker has formed a 1,2-disubstituted 1,2,3-triazole with the alkyne group on the insulin.

FIG. 4A, FIG. 4B, FIG. 4C, FIG. 4D, FIG. 4E, FIG. 4F, FIG. 4G, FIG. 4H, FIG. 4I, FIG. 4J, FIG. 4K, FIG. 4L, FIG. 4M, FIG. 4N, FIG. 4O, and FIG. 4P show exemplary insulin-incretin conjugates in which the Nle amino acid of particular incretins is conjugated to the amino group of the Phenylalanine (Phe) at position B1 of the B-chain peptide. The “*” indicates that the incretin has the amino acid sequence and structure of the indicated incretin but wherein the azide group of the linker has formed a 1,2-disubstituted 1,2,3-triazole with the alkyne group on the insulin.

FIG. 5 shows an exemplary insulin-incretin conjugate in which the Nle amino acid of PEP74* is conjugated to the amino group of the Phe at position B1 of the B-chain peptide. The “*” indicates that the incretin has the amino acid sequence and structure of the indicated incretin but wherein the azide group of the linker has formed a 1,4,5-trisubstituted 1,2,3-triazole with the alkyne group on the insulin.

FIG. 6A, FIG. 6B, FIG. 6C, and FIG. 6D show exemplary insulin-incretin conjugates in which the epsilon amino group of Lys of the incretin is conjugated to the amino group of the Phe at position B1 of the B-chain peptide. The “*” indicates that the incretin has the amino acid sequence and structure of the indicated incretin but wherein the azide group of the linker has formed a 1,2-disubstituted 1,2,3-triazole with the alkyne group on the insulin.

FIG. 7 shows that the length of the linking moiety at B1 has an effect on the ratio of glucagon (GCG) activity to GLP-1 activity.

FIG. 8 shows that the length of the linking moiety at B29 has an effect on the activity of the insulin at the insulin receptor ratio of GCG activity to GLP-1 activity.

FIG. 9A, FIG. 9B, FIG. 9C, FIG. 9D, FIG. 9E, FIG. 9F, FIG. 9G, FIG. 9H, FIG. 9I, FIG. 9J, FIG. 9K, and FIG. 9L show exemplary insulin-incretin conjugates in which the Norleucine (Nle) amino acid of the incretin is conjugated to the amino group of the Phe at position B1 of the B-chain peptide. The “*” indicates that the incretin has the amino acid sequence and structure of the indicated incretin but wherein the azide group of the linker has formed a 1,2-disubstituted 1,2,3-triazole with the alkyne group on the insulin.

FIG. 10A, FIG. 10B, FIG. 10C, FIG. 10D, FIG. 10E, FIG. 10F, and FIG. 10G show exemplary insulin-incretin conjugates in which the epsilon amino group of Lys of the incretin is conjugated to the amino group of the Phenylalanine (Phe) at position B1 of the B-chain peptide. The “*” indicates that the incretin has the amino acid sequence and structure of the indicated incretin but wherein the azide group of the linker has formed a 1,2-disubstituted 1,2,3-triazole with the alkyne group on the insulin.

FIG. 11 shows exemplary insulin-incretin conjugates CON106 and CON107.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides insulin-incretin conjugates that are anticipated to impart a beneficial addition to insulin therapies for diabetes. For example, linking an incretin peptide having agonist activity at the GCG receptor to an insulin molecule may enhance targeting of the conjugate to the liver since the GCG receptor is predominately located in the liver. Targeting the conjugate to the liver may be desirable since the liver is primarily involved in glucose production not glucose utilization. Thus, targeting the liver may provide a safer approach to shutting off glucose production than would occur when the insulin contacts other tissues such as muscle or fat, where in addition to turning off glucose production it also stimulates glucose use leading to a higher risk of hypoglycemia. Also, there are GCG receptors present on the alpha cells of the pancreas. Delivering the conjugate to the alpha cells may suppress additional glucagon production or make the alpha cell more sensitive to hypoglycemia. It is also anticipated that the presence of GCG in the conjugates may serve as a buffer on the activity of the insulin to provide a more baseline activity and thus avoid spikes in blood glucose levels. Furthermore, whereas insulin stimulates lipogenesis in fat cells and weight gain, GCG increases lipolysis and energy expenditure and effects a decrease in weight gain, which may be beneficial in countering the weight gain that may occur during insulin therapies.

Similarly, it is anticipated that conjugates of insulin with other GCG-related peptides including the incretins GLP-1 and GIP and other related peptides having activity at the GLP-1 and/or GIP receptors may produce conjugates having beneficial properties. For example, GLP-1 receptor agonist-insulin conjugate may be targeted to the hypothalamus, to decrease appetite as well as reduce blood glucose. Alternatively or additionally, the GLP-1 receptor agonist-insulin conjugate may be targeted to the beta cells to drive anabolic response (increase islet beta cells production of insulin).

The incretin-insulin conjugates herein are also suitable for further structural enhancements that are envisioned to yield improved therapeutic index, through the use of prodrug chemistry; extended duration of action, by linkage of plasma proteins such as albumin, or other modifications, including pegylation and acylation; and enhanced physical stability, by glycosylation. The preparation of single chain insulin analogs using a C-peptide or peptide linker also provides a novel structural location for where many of these chemical modifications can be successfully deployed. The primary use of the conjugates disclosed herein would be in the treatment of insulin-dependent diabetes, including for example, T1DM, T2DM, and gestational diabetes.

Insulin-Incretin Conjugates

The insulin-incretin conjugate of the present invention comprises an insulin molecule having agonist activity at the insulin receptor conjugated via a non-peptide linking moiety to a peptide having incretin activity, wherein the non-peptide linking moiety comprises a 1,4-disubstituted 1, 2, 3-triazole and the incretin is a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, the gastric inhibitory protein (GIP) receptor, or both the GLP-1 receptor and the GCG receptor or both the GLP-1 receptor and the GIP receptor. FIG. 1A provides a schematic representation of an insulin-incretin conjugate.

In specific embodiments, the insulin may have an EC₅₀at the insulin receptor of about 20 nM or less, 10 nM or less, 5 nM or less, or between 1 to nM. In specific embodiments, the incretin may have an EC₅₀at the GLP-1 receptor of about 10 nM or less, 5 nM or less, 1 nM or less, or between 0.01 nM and 1 nM. In specific embodiments, the incretin may have an EC₅₀at the GIP receptor of about 10 nM or less, 5 nM or less, 1 nM or less, or between 0.01 nM and 1 nM. In specific embodiments, the incretin may have an EC₅₀at the GCG1 receptor of about 10 nM or less, 5 nM or less, 1 nM or less, or between 0.01 nM and 1 nM. In specific embodiments, the incretin is a co-agonist in which the activity at the GLP-1 receptor and the GCG receptor are relatively balanced.

In particular embodiments, the insulin-incretin conjugate comprises (i) an insulin molecule having insulin activity and comprising an alkyne group conjugated to a peptide having incretin activity and comprising an azide group under conditions wherein the alkyne group and the azide group form a linking moiety comprising a 1,4-disubstituted 1, 2, 3-triazole or (ii) an insulin molecule comprising an azide group conjugated to an incretin peptide comprising an alkyne group under conditions wherein the azide group and the alkyne group form a 1,4-disubstituted 1, 2, 3-triazole.

In particular embodiments, the peptide comprises (i) a first linker arm having a proximal end linked to an amino acid of the peptide and a distal end linked to an azide group and the insulin molecule comprises a second linker arm having a proximal end linked to an amino acid of the insulin molecule and a distal end linked to an alkyne group; or (ii) the compound of claim 1, wherein the peptide comprises a first linker arm having a proximal end linked to an amino acid of the peptide and a distal end linked to an alkyne group and the insulin molecule comprises a second linker arm having a proximal end linked to an amino acid of the insulin molecule and a distal end linked to an azide group; or (c) a propargyl-Glycine and the insulin molecule comprises a linker arm having a proximal end linked to the amino group of an amino acid of the insulin molecule and a distal end linked to an azido group, wherein the azido group and the alkynyl group form the 1,4-disubstituted 1,2,3-triazole.

In a particular embodiment, the insulin-incretin conjugate comprises an insulin molecule having agonist activity at the insulin receptor conjugated via a non-peptide linking moiety to a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, or both the GLP-1 receptor and the GCG receptor, wherein the non-peptide linking moiety comprises a 1,4-disubstituted 1, 2, 3-triazole; or in a particular embodiment, the insulin-incretin conjugate comprises an insulin molecule having agonist activity at the insulin receptor conjugated via a non-peptide linking moiety to a peptide having agonist activity at the gastric inhibitory protein (GIP) receptor or both the GLP-1 receptor and the GIP receptor, wherein the non-peptide linking moiety comprises a 1,4-disubstituted 1, 2, 3-triazole.

In particular embodiments of the insulin-incretin conjugates herein, the insulin-incretin conjugate comprises (i) an insulin molecule comprising an alkyne group conjugated to an incretin peptide comprising an azide group under conditions wherein the alkyne group and the azide group form a linking moiety comprising a 1,4-disubstituted 1, 2, 3-triazole or (ii) an insulin molecule comprising an azide group conjugated to an incretin peptide comprising an alkyne group under conditions wherein the azide group and the alkyne group form a 1,4-disubstituted 1, 2, 3-triazole; or (iii) a propargyl-Glycine and the insulin molecule comprises a linker arm having a proximal end linked to the amino group of an amino acid of the insulin molecule and a distal end linked to an azido group, wherein the azido group and the alkynyl group form the 1,4-disubstituted 1,2,3-triazole.

In particular embodiments, the peptide comprises (a) a first linker arm having a proximal end linked to an amino acid of the peptide and a distal end linked to an azide group and the insulin molecule comprises a second linker arm having a proximal end linked to an amino acid of the insulin molecule and a distal end linked to an alkyne group; or (b) the compound of claim 1, wherein the peptide comprises a first linker arm having a proximal end linked to an amino acid of the peptide and a distal end linked to an alkyne group and the insulin molecule comprises a second linker arm having a proximal end linked to an amino acid of the insulin molecule and a distal end linked to an azide group.

In particular embodiments, the linking moiety comprises the formula

embedded image

In particular aspects, the peptide optionally includes a protecting group covalently joined to the N-terminal amino group. A protecting group covalently joined to the N-terminal amino group of the peptide reduces the reactivity of the amino terminus under in vivo conditions. Amino protecting groups include —C_1-10alkyl, —C_1-10substituted alkyl, —C_2-10alkenyl, —C_2-10substituted alkenyl, aryl, —C_1-6alkyl aryl, —C(O)—(CH₂)_1-6—COOH, —C(O)—C_1-6alkyl, —C(O)-aryl, —C(O)—O—C_1-6alkyl, or —C(O)—O-aryl. In particular embodiments, the amino terminus protecting group is selected from the group consisting of acetyl, propyl, succinyl, benzyl, benzyloxycarbonyl, and t-butyloxycarbonyl. Deamination of the N-terminal amino acid is another modification that is contemplated for reducing the reactivity of the amino terminus under in vivo conditions.

In particular aspects, the peptide may be modified to have a protecting group covalently joined to the C-terminal carboxy group, which reduces the reactivity of the carboxy terminus under in vivo conditions. For example, carboxylic acid groups of the peptide, whether carboxyl-terminal or side chain, may be provided in the form of a salt of a pharmacologically-acceptable cation or esterified to form a C_1-6ester, or converted to an amide of formula NRR₂wherein R and R₂are each independently H or C_1-6alkyl, or combined to form a heterocyclic ring, such as a 5- or 6-membered ring. The carboxy terminus protecting group is preferably attached to the α-carbonyl group of the last amino acid. Carboxy terminus protecting groups include, but are not limited to, amide, methylamide, and ethylamide. Amino groups of the peptide, whether N-terminal or side chain, may be in the form of a pharmacologically-acceptable acid addition salt, such as the HCl, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric, and other organic salts, or may be modified to C_1-6alkyl or dialkyl amino or further converted to an amide.

The present invention further provides a conjugate comprising the formula

A-LM-B

wherein A is human insulin molecule or human insulin analog molecule; B is an incretin peptide (e.g., glucagon, GLP-1, or GIP) or a glucagon peptide modified to have agonist activity at the GLP1 receptor, agonist activity at the GIP receptor, agonist the GLP1 and GCG receptors, or agonist activity at the GLP-1 and GIP receptors; LM is a linking moiety comprising a cyclic or acyclic bisamide, a heterocycle and a substituted heterocycle, a C₁-C₅₀hydrocarbon chain or substituted hydrocarbon chain, a PEG_nwherein n is 1-50, a (PEG₂)_nwherein n is 1-50, a (PEG₂)_n-(γGlu)_p-C_nwherein each n is independently 1-50 and p is 1 or 2, a (PEG₂)_n-C_nwherein each n is independently is 1-50, a (PEG)_n(PEG)_nwherein each n is independently 1-50, a PEG_n-(Lys-(γGlu)_p-C_n)—C_nwherein each n is independently 1-50 and p is 1 or 2, or a C₅-Lys(γE-C_n)-PEG_nwherein each n is independently 1-50.

In particular embodiments, LM is selected from a straight or branched, saturated or unsaturated, optionally substituted C_1-30hydrocarbon chain wherein one or more methylene units of Y are optionally and independently replaced by —O—, —S—, —N(R)—, —C(O)—, C(O)O—, OC(O)—, —N(R)C(O)—, —C(O)N(R)—, —S(O)—, —S(O)₂—, —N(R)SO₂—, SO₂N(R)—, a heterocyclic group, an aryl group, or a heteroaryl group, wherein each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety.

In particular embodiments, the human insulin molecule or human insulin analog molecule may be a heterodimer comprising an A-chain peptide and a B-chain peptide connected by disulfide linkages characteristic of human insulin or a single-chain insulin molecule comprising the disulfide linkages characteristic of human insulin wherein the C-terminal amino acid of the B-chain is conjugated to the N-terminal amino acid of the A-chain peptide by a peptide or non-peptide linker.

In particular embodiments, the N-terminal amino acid of the A-chain peptide of the human insulin or human insulin analog molecule is conjugated via LM to an amino acid in the incretin peptide or modified glucagon peptide; or, the N-terminal amino acid of the B-chain peptide of the human insulin or human insulin analog molecule is conjugated via LM to an amino acid in the incretin peptide or modified glucagon peptide; or, the epsilon amino group of a Lysine in the human insulin or human insulin analog molecule is conjugated via LM to an amino acid in the incretin peptide or modified glucagon peptide.

In particular embodiments, the N-terminal amino acid of the A-chain peptide of the human insulin or human insulin analog molecule is conjugated via LM to a Lysine or Norleucine in the incretin peptide or modified glucagon peptide; or, the N-terminal amino acid of the B-chain peptide of the human insulin or human insulin analog molecule is conjugated via LM to a Lysine or Norleucine in the incretin peptide or modified glucagon peptide; or, the epsilon amino group of a Lysine in the human insulin or human insulin analog molecule is conjugated via LM to a Lysine or Norleucine in the incretin peptide or modified glucagon peptide.

Incretin

The incretin comprising the insulin-incretin conjugate may be any peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, the gastric inhibitory protein (GIP) receptor, or both the GLP-1 receptor and the GCG receptor or both the GLP-1 receptor and the GIP receptor. In particular embodiments, the incretin is a glucagon peptide modified to have agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, the gastric inhibitory protein (GIP) receptor, or both the GLP-1 receptor and the GCG receptor or both the GLP-1 receptor and the GIP receptor.

In particular embodiments, the peptide comprises a modified glucagon peptide comprising the amino acid sequence

(SEQ ID NO: 1)

HSQGTFTSDYSKYLDERAAQDFVQWLLDT,

which further includes at least the following modifications: (i) a substitution of the amino acid at position 2 with an amino acid that renders the peptide resistant to cleavage and inactivation by dipeptidyl peptidase IV; (ii) a lipid moiety covalently linked to the peptide at a lysine residue substituted for the tyrosine residue at position 10 or the glutamine at position 20 of the peptide; (iii) an azide group or an alkyne group conjugated to an amino acid at position 20, 21, 24, 30, or 31; (iv) 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional amino acid substitutions in addition to the substitution at position 2; and optionally, a protecting group that is joined to the C-terminal carboxy group and/or the N-terminal amino group. In embodiments in which the modified glucagon peptide has agonist activity at the GIP receptor, the Histidine at position 1 is substituted Tyrosine, Phenylalanine, Tryptophan, or other amino acid with an aromatic group.

In general, the peptide comprises a substitution of the Ser at position 2 with Val, Ile, Asp, Glu, Met, Trp, Asn, D-Ala, D-Ser, α-methyl-Ser, α-methyl-D-Ser or α-aminoisobutyric acid (aib or U). In particular embodiments, the Ser is substituted with D-Ser or aib. These substitutions at position 2 render the peptide resistant to DPP-4 and active at the GLP-1 receptor. Peptides with a substitution are co-agonists of the GCG and the GLP-1 receptors.

In particular embodiments, the peptide includes a substitution of the Glu at position 16 with aib, Asn, Ser, or Ala.

In particular embodiments, the insulin molecule comprises an alkyne group and the peptide agonist activity is selective for the GLP-1 receptor and comprises the structure

(SEQ ID NO: 2)

HX²X³GTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹X²²VX²⁴X²⁵X²⁶X²⁷

X²⁸X²⁹X³⁰X³¹,

wherein X²is amionisobutyric acid (Aib), Gly, D-Serine (s), alpha-methyl Serine (αMS), or alpha-methyl D-Serine (αMs);

X³is Val, Glu or Asp;

X⁹is Asp or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to a lipid moiety;

X¹²is Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²²is Phe or αMF;

X²⁴is Glutamine, Nle(εN₃), or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal azide group;

X²⁵is Tryptophan or alpha-methyl Tryptophan (αMW);

X²⁶is Leucine or αML;

X²⁷is Methionine, Leucine, Methionine sulfoxide, or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

X³⁰is Arginine, Lysine, or Nle(εN₃), or X³⁰is absent; and

X³¹is Glycine, γGlu, Nle(εN₃), or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal azide group, or X³¹is absent; and

wherein the C-terminal amino acid optionally is amidated, and with the proviso that either X¹⁰is a Lysine residue conjugated via its epsilon amino acid to the lipid moiety and one of X²⁰, X²¹, X²⁴, X³⁰, or X³¹comprises the azide group or X²⁰is a Lysine residue conjugated via its epsilon amino acid to the lipid moiety and one of X²¹, X²⁴, X³⁰, or X³¹comprises the azide group.

In particular embodiments, the insulin molecule comprises an azide group and the peptide agonist activity is selective for the GLP-1 receptor and comprises the structure

(SEQ ID NO: 3)

HX²X³GTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹X²²V-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X³is Val, Glu, or Asp;

X⁹is Asp or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to a lipid moiety;

X¹²is Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁰is Glutamine or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal alkyne group or to a fatty acid or fatty diacid;

X²¹is Aspartic acid, αMD, Alkynylnorleucine (Norleucine conjugated via its epsilon carbon to an alkyne group (Nle(ε-alkyne))), or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal alkyne group;

X²²is Phe or alpha-methyl Phenylalanine (αMF);

X²⁴is Glutamine, Nle(ε-alkyne), or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal alkyne group;

X²⁵is Tryptophan or alpha-methyl Tryptophan (αMW);

X²⁶is Leucine or αML;

X²⁷is Methionine, Leucine, methionine sulfoxide, or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

X³⁰is Arginine, Lysine, or Nle(ε-alkyne), or X³⁰is absent; and

X³¹is Glycine, γGlu, Nle(ε-alkyne), or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal alkyne group, or X³¹is absent; and

wherein the C-terminal amino acid optionally is amidated, and with the proviso that either X¹⁰is a Lysine residue conjugated via its epsilon amino acid to the lipid moiety and one of X²⁰, X²¹, X²⁴, X³⁰, or X³¹comprises the alkyne group or X²⁰is a Lysine residue conjugated via its epsilon amino acid to the lipid moiety and one of X²¹, X²⁴, X³⁰, or X³¹comprises the alkyne group.

In particular embodiments, the insulin molecule comprises an alkyne group and the peptide has agonist activity at the GLP-1 and GCG receptors and comprises the structure

(SEQ ID NO: 4)

HX²QGTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹X²²V-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X⁹is Asp or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to a lipid moiety;

X¹²is Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁰is Glutamine or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal azide group or to a fatty acid or fatty diacid;

X²¹is Aspartic acid, αMD, Azidonorleucine (Norleucine conjugated via its epsilon carbon to an azide group (Nle(εN₃))), or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal azide group;

X²²is Phe or alpha-methyl Phenylalanine (αMF);

X²⁴is Glutamine, Nle(εN₃), or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal azide group;

X²⁵is Tryptophan or alpha-methyl Tryptophan (αMW);

X²⁶is Leucine or αML;

X²⁷is Methionine, Leucine, methionine sulfoxide, or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

In particular embodiments, the insulin molecule comprises an azide group and the peptide has agonist activity at the GLP-1 and GCG receptors and comprises the structure

(SEQ ID NO: 5)

HX²QGTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹X²²V-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X⁹is Asp or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to a lipid moiety;

X¹²is Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁶is Leucine or αML;

X²⁷is Methionine, Leucine, methionine sulfoxide, or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

wherein the C-terminal amino acid optionally is amidated, and with the proviso that either X¹⁰is a Lysine residue conjugated via its epsilon amino acid to the lipid moiety and one of X²⁰, X²¹, X²⁴, X³⁰, or X³¹comprises the alkyne group or X²⁰is a Lysine residue conjugated via its epsilon amino acid to the lipid moiety and one of X²¹, X²⁴, X³⁰, or X³¹comprises the alkyne group.

In particular embodiments, the insulin molecule comprises an alkyne group and the peptide has agonist activity predominantly at the GLP-1 receptor and GIP receptor and comprises the structure

(SEQ ID NO: 6)

X¹X²X³GTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹X²²V-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X¹is Tyrosine, Phenylalanine, Tryptophan, or other amino acid with an aromatic group;

X²is amionisobutyric acid (Aib), Gly, D-Serine (s), or alpha-methyl Serine (αMS);

X³is Val, Glu, or Asp;

X⁹is Asp or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to a lipid moiety;

X¹²is Isoleucine, Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁰is Glutamine or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal azide group or to a fatty acid or fatty diacid;

X²¹is Aspartic acid, αMD, Azidonorleucine (Norleucine conjugated via its epsilon carbon to an azide group (Nle(εN₃))), or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal azide group;

X²²is Phe or alpha-methyl Phenylalanine (αMF),

X²⁴is Glutamine, Nle(εN₃), or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal azide group;

X²⁵is Tryptophan or alpha-methyl Tryptophan (αMW);

X²⁶is Leucine or αML;

X²⁷is Met, Leucine, methionine sulfoxide, or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

In particular embodiments, the insulin molecule comprises an azide group and the peptide has agonist activity at the GLP-1 receptor and GIP receptor and comprises the structure

(SEQ ID NO: ⁷)

X¹X²X³GTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹X²²V-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X¹is Tyrosine, Phenylalanine, Tryptophan, or other amino acid with an aromatic group;

X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X³is Val, Glu, or Asp;

X⁹is Asp or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to a lipid moiety;

X¹²is Isoleucine, Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁰is Glutamine or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal alkyne group or to a fatty acid or fatty diacid;

X²¹is Aspartic acid, αMD, Alkynylnorleucine (Norleucine conjugated via its epsilon carbon to an alkyne group (Nle(ε-alkyne))), or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal alkyne group;

X²²is Phe or alpha-methyl Phenylalanine (αMF), X²⁴is Glutamine, Nle(ε-alkyne), or Lysine conjugated via its epsilon amino group to a non-peptide linker comprising a terminal alkyne group;

X²⁵is Tryptophan or alpha-methyl Tryptophan (αMW);

X²⁶is Leucine or αML;

X²⁷is Methionine, Leucine, methionine sulfoxide, or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

wherein the C-terminal amino acid optionally is amidated, and with the proviso that either X¹⁰is a Lysine residue conjugated via its epsilon amino acid to the lipid moiety and one of X²⁰, X²¹, X²⁴, X³⁰, or X³¹comprises the alkyne group or X²⁰is a Lysine residue conjugated via its epsilon amino acid to the lipid moiety and one of X²¹, X²⁴, X³⁰, or X³¹comprises the alkyne group.

In particular embodiments, the insulin molecule comprises an alkyne group and the peptide has agonist activity at the GLP-1, GIP, and GCG receptors and comprises the structure

(SEQ ID NO: 8)

X¹X²QGTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹X²²V-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X¹is Tyrosine, Phenylalanine, Tryptophan, or other amino acid with an aromatic group;

X²is amionisobutyric acid (Aib), Gly, D-Serine (s), or alpha-methyl Serine (αMS);

X⁹is Asp or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to a lipid moiety;

X¹²is Isoleucine, Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁶is Leucine or αML;

X²⁷is methionine, Leucine, methionine sulfoxide, or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

In particular embodiments, the insulin molecule comprises an azide group and the peptide has agonist activity at the GLP-1, GIP, and GCG receptors and comprises the structure

(SEQ ID NO: 9)

X¹X²QGTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹FV-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X¹is Tyrosine, Phenylalanine, Tryptophan, or other amino acid with an aromatic group;

X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X⁹is Asp or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to a lipid moiety;

X¹²is Isoleucine, Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁶is Leucine or αML;

X²⁷is methionine, Leucine, methionine sulfoxide, or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

wherein the C-terminal amino acid optionally is amidated, and with the proviso that either X¹⁰is a Lysine residue conjugated via its epsilon amino acid to the lipid moiety and one of X²⁰, X²¹, X²⁴, X³⁰, or X³¹comprises the alkyne group or X²⁰is a Lysine residue conjugated via its epsilon amino acid to the lipid moiety and one of X²¹, X²⁴, X³⁰, or X³¹comprises the alkyne group.

The lipid moiety may be a monocarboxylic acid comprising an aliphatic chain of 13 to 20 methylene groups (fatty acid) wherein one end of the molecule is the proximal end and the other end is the distal end and only one of the proximal end and the distal end has a carboxyl (COOH) group. The fatty acid may be represented by the structure HO₂C(CH₂)_nCH₃, wherein n is 11, 12, 13, 14, 15, 16, 17, or 18. The fatty acid may have one of the following structures

embedded image

The lipid moiety may be an α,ω-dicarboxylic acid comprising an aliphatic chain of 13 to 20 methylene groups (fatty diacid) wherein one end of the molecule is the proximal end and the other end is the distal end and wherein the proximal end and the distal end both have a carboxyl (COOH) group. The fatty diacid may be represented by the structure HO₂C(CH₂)_nCO₂H, wherein n is 11, 12, 13, 14, 15, 16, 17, or 18. The fatty diacid may have one of the following structures

embedded image

As a component of the peptide, the acid functionality at the proximal end of the fatty diacid is conjugated to the amino group of a linker in a C(O)—NH linkage and the acid functionality at the distal end of the fatty diacid is a free carboxyl group (COOH). The COOH group at the distal end helps confer a longer half-life to the peptide by its ability to non-covalently bind to serum albumin, a known carrier for fatty acids in serum. The COOH group enhances duration of action as it provides a better non-covalent interaction with serum albumin than peptides that have been acylated using a fatty acid, which bind serum albumin less efficiently and form a less stable non-covalent interaction with the serum albumin.

When the fatty acid or diacid is conjugated to a linking moiety or linker, it is subsequently referred to as a fatty acid component. The linker may be PEG₂(8-amino-3,6-dioxaoctanoic acid) linked to Gamma-Glutamic acid (gamma-Glu, γGlu, or γE), which has the structure

embedded image

or the linker may be Gamma-Glutamic acid-gamma glutamic acid (gamma-Glu-gamma-Glu, or γGlu-γGlu, or γEγE), which has the structure

embedded image

The structure of K(PEG₂PEG₂γE-fatty acid) wherein the linker is PEG₂PEG₂γE and the fatty acid component comprises C14, C16, C17, C18, C19, or C20 fatty acid is represented by

embedded image

wherein n is 7, 9, 10, 11, 12, 13, or 14 respectively, and the wavy lines represent the bonds between adjacent amino acids in the peptide sequence.

The structure of K(γEγE-fatty acid) wherein the linker is γEγE and the fatty acid component comprises C14, C16, C17, C18, C19, or C20 fatty acid is represented by

embedded image

wherein n is 7, 9, 10, 11, 12, 13, or 14, respectively, and the wavy lines represent the bonds between adjacent amino acids in the peptide sequence.

The structure of K(PEG₂PEG₂γE-fatty acid) wherein the linker is PEG₂PEG₂γE and the fatty acid component comprises C14, C16, C17, C18, C19, or C20 fatty diacid is represented by

embedded image

wherein n is 7, 9, 10, 11, 12, 13, or 14 respectively, and the wavy lines represent the bonds between adjacent amino acids in the peptide sequence.

The structure of K(γEγE-fatty acid) wherein the linker is γEγE and the fatty acid component comprises C14, C16, C17, C18, C19, or C20 fatty diacid is represented by

embedded image

wherein n is 7, 9, 10, 11, 12, 13, or 14, respectively, and the wavy lines represent the bonds between adjacent amino acids in the peptide sequence.

In particular aspects, the peptide may comprise a lysine residue at the C-terminus that is conjugated to a γE residue to provide a KγE at position 30 in the peptide, which is represented by

embedded image

wherein the wavy lines represent the bonds between adjacent amino acids in the peptide sequence.

In a further embodiment, the insulin molecule comprises an alkyne group and the peptide has agonist activity at the GLP-1 and GCG receptors and comprises the structure

(SEQ ID NO: 10)

HX²QGTFTSX⁹X¹⁰SX¹²YXL⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹FV-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X⁹is Serine or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to γGlu-γGlu-C16;

X¹²is Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁰is Glutamine or Lysine conjugated via its epsilon amine group to PEG₂-C₅N₃, PEG₂PEG₂-C₅N₃, PEG₂PEG₂-γGlu-C₁₆N₃, PEG₂PEG₂-γGlu-C₁₈—OH, or PEG₂PEG₂γE-C₂₀—OH;

X²¹is Aspartic acid, alpha-methyl Phenylalanine (αMF), αMD, Azidonorleucine (Norleucine conjugated via its epsilon carbon to an azide group (Nle(εN₃))), or Lys conjugated via its epsilon amine group to PEG₂-C₅N₃, PEG₂PEG₂-C₅N₃, or PEG₂PEG₂-γGlu-C₁₆N₃;

X²⁴is Glutamine, Nle(εN₃), or Lysine conjugated to PEG₂PEG₂-γGlu-C₁₆N₃;

X²⁵is Tryptophan or alpha-methyl Tryptophan (αMW);

X²⁶is Leucine or αML;

X²⁷is Leucine or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

X³⁰is Arginine, Lysine, or Nle(εN₃), or X³⁰is absent; and

X³¹is Glycine, γGlu, Nle(εN₃), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆N₃, PEG₂-C₅N₃or PEG₂PEG₂-C₅N₃, or X³¹is absent; and

wherein the C-terminal amino acid optionally is amidated, and with the proviso that either X¹⁰is a Lysine residue conjugated via its epsilon amino group to a γGlu-γGlu-C₁₆and one of X²⁰, X²¹, X²⁴, X³⁰, or X³¹comprises the azide or N₃group or X²⁰is a Lysine residue conjugated via its epsilon amino group to the PEG₂PEG₂-γGlu-C₁₈—OH or the PEG₂PEG₂γE-C₂₀—OH and one of X²¹, X²⁴, X³⁰, or X³¹comprises the azide or N₃group.

In a further embodiment, the insulin molecule comprises an alkyne group and the peptide has agonist activity at the GLP-1 and GCG receptors and comprises the structure

(SEQ ID NO: 11)

HX²QGTFTSX⁹X¹⁰SX¹²YXL⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹FV-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X⁹is Serine or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to γGlu-γGlu-C₁₆;

X¹²is Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁰is Glutamine or Lysine conjugated via its epsilon amine group to PEG₂-C₅N₃, PEG₂PEG₂-C₅-alkyne, PEG₂PEG₂-γGlu-C₁₆-alkyne, PEG₂PEG₂-γGlu-C₁₈—OH, or PEG₂PEG₂γE-C₂₀—OH;

X²¹is Aspartic acid, alpha-methyl Phenylalanine (αMF), αMD, Alkynylnorleucine (Norleucine conjugated via its epsilon carbon to an alkyne group (Nle(ε-alkyne))), or Lys conjugated via its epsilon amine group to PEG₂-C₅-alkyne, PEG₂PEG₂-C₅-alkyne, or PEG₂PEG₂-γGlu-C₁₆-alkyne;

X²⁴is Glutamine, Nle(ε-alkyne), or Lysine conjugated to PEG₂PEG₂-γGlu-C₁₆-alkyne;

X²⁵is Tryptophan or alpha-methyl Tryptophan (αMW);

X²⁶is Leucine or αML;

X²⁷is Leucine or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

X³⁰is Arginine, Lysine, or Nle(ε-alkyne), or X³⁰is absent; and

X³¹is Glycine, γGlu, Nle(ε-alkyne), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆-alkyne, PEG₂-C₅-alkyne, PEG₂PEG₂-C₅-alkyne, or X³¹is absent; and

wherein the C-terminal amino acid optionally is amidated, and with the proviso that either X¹⁰is a Lysine residue conjugated via its epsilon amino group to a γGlu-γGlu-C₁₆and one of X²⁰, X²¹, X²⁴, X³⁰, or X³¹comprises the -alkyne or X²⁰is a Lysine residue conjugated via its epsilon amino group to the PEG₂PEG₂-γGlu-C₁₈—OH or the PEG₂PEG₂γE-C₂₀—OH and one of X²¹, X²⁴, X³⁰, or X³¹comprises the -alkyne.

In a further embodiment, the insulin molecule comprises an alkyne group and the peptide has agonist activity selective for the GLP-1 receptor and comprises the structure

(SEQ ID NO: 12)

HX²X³GTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹FV-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X³is Glu or Asp;

X⁹is Serine or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to γGlu-γGlu-C₁₆;

X¹²is Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁶is Leucine or αML;

X²⁷is Leucine or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

In a further embodiment, the insulin molecule comprises an alkyne group and the peptide has agonist activity selective for the GLP-1 receptor and comprises the structure

(SEQ ID NO: 13)

HX²X³GTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹FV-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X³is Glu or Asp;

X⁹is Serine or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to γGlu-γGlu-C₁₆;

X¹²is Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁶is Leucine or αML;

X²⁷is Leucine or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

wherein the C-terminal amino acid optionally is amidated, and with the proviso that either X¹⁰is a Lysine residue conjugated via its epsilon amino group to a γGlu-γGlu-C₁₆and one of X²⁰, X²¹, X²⁴, X³⁰, or X³¹comprises the -alkyne or X²⁰is a Lysine residue conjugated via its epsilon amino group to the PEG₂PEG₂-γGlu-C₁₈—OH or the PEG₂PEG₂γE-C₂₀—OH and one of X²¹, X²⁴, X³⁰, or X³¹comprises the -alkyne.

In a further embodiment, the insulin molecule comprises an alkyne group and the peptide has agonist activity at the GLP-1 and GIP receptors and comprises the structure

(SEQ ID NO: 14)

X¹X²X³GTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹FV-

x²⁴x²⁵X²⁶x²⁷X²⁸x²⁹x³⁰x³¹,

wherein X¹is Tyrosine, Phenylalanine, Tryptophan, or other amino acid with an aromatic group;

X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X³is Glu or Asp;

X⁹is Serine or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to γGlu-γGlu-C₁₆;

X¹²is Isoleucine, Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁶is Leucine or αML;

X²⁷is Leucine or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

In a further embodiment, the insulin molecule comprises an alkyne group and the peptide has agonist activity at the GLP-1 and GIP receptors and comprises the structure

(SEQ ID NO: 15)

X¹X²X³GTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹FV-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X¹is Tyrosine, Phenylalanine, Tryptophan, or other amino acid with an aromatic group;

X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X³is Glu or Asp;

X⁹is Serine or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to γGlu-γGlu-C₁₆;

X¹²is Isoleucine, Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁰is Glutamine or Lysine conjugated via its epsilon amine group to PEG₂-C₅N₃, PEG₂PEG₂-C₅-alkyne, PEG₂PEG₂-γGlu-C₁₆-alkyne, PEG₂PEG₂-γGlu-C₁₈—OH, or PEG₂PEG₂γE-C₂₀—OH;

X²¹is Aspartic acid, alpha-methyl Phenylalanine (αMF), αMD, Alkynylnorleucine (Norleucine conjugated via its epsilon carbon to an alkyne group (Nle(ε-alkyne))), or Lys conjugated via its epsilon amine group to PEG₂-C₅-alkyne, PEG₂PEG₂-C₅-alkyne, or PEG₂PEG₂-γGlu-C16-alkyne;

X²⁴is Glutamine, Nle(ε-alkyne), or Lysine conjugated to PEG₂PEG₂-γGlu-C₁₆-alkyne;

X²⁵is Tryptophan or alpha-methyl Tryptophan (αMW);

X²⁶is Leucine or αML;

X²⁷is Leucine or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

wherein the C-terminal amino acid optionally is amidated, and with the proviso that either X¹⁰is a Lysine residue conjugated via its epsilon amino group to a γGlu-γGlu-C₁₆and one of X²⁰, X²¹, X²⁴, X³⁰, or X³¹comprises the -alkyne or X²⁰is a Lysine residue conjugated via its epsilon amino group to the PEG₂PEG₂-γGlu-C₁₈—OH or the PEG₂PEG₂γE-C₂₀—OH and one of X²¹, X²⁴, X³⁰, or X³¹comprises the -alkyne.

In a further embodiment, the insulin molecule comprises an alkyne group and the peptide has agonist activity at the GLP-1, GIP, and GCG receptors and comprises the structure

(SEQ ID NO: 16)

X¹X²QGTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹FV-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X¹is Tyrosine, Phenylalanine, Tryptophan, or other amino acid with an aromatic group;

X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X⁹is Serine or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to γGlu-γGlu-C₁₆;

X¹²is Isoleucine, Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁶is Leucine or αML;

X²⁷is Leucine or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

In a further embodiment, the insulin molecule comprises an alkyne group and the peptide has agonist activity at the GLP-1, GIP, and GCG receptors and comprises the structure

(SEQ ID NO: 17)

X¹X²QGTFTSX⁹X¹⁰SX¹²YX¹⁴DX¹⁶X¹⁷X¹⁸AX²⁰X²¹FV-

X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹,

wherein X¹is Tyrosine, Phenylalanine, Tryptophan, or other amino acid with an aromatic group;

X²is aminoisobutyric acid (Aib), D-Serine (s), or alpha-methyl Serine (αMS);

X⁹is Serine or alpha-methyl Aspartic acid (αMD);

X¹⁰is Tyr or Lys conjugated to γGlu-γGlu-C₁₆;

X¹²is Isoleucine, Lysine, Leucine, or Serine;

X¹⁴is Leu of alpha-methyl Leucine (αML);

X¹⁶is Glutamic acid, Asparagine, Serine, Alanine, or Aib;

X¹⁷is Arginine or Lysine;
X¹⁸is Alanine or Arginine;

X²⁶is Leucine or αML;

X²⁷is Leucine or L-methionine sulphone (2);

X²⁸is Aspartic acid, Alanine, Lysine, Asparagine, γGlu, Glutamine, or αMD;

X²⁹is Threonine or Glycine;

wherein the C-terminal amino acid optionally is amidated, and with the proviso that either X¹⁰is a Lysine residue conjugated via its epsilon amino group to a γGlu-γGlu-C₁₆and one of X²⁰, X²¹, X²⁴, X³⁰, or X³¹comprises the -alkyne or X²⁰is a Lysine residue conjugated via its epsilon amino group to the PEG₂PEG₂-γGlu-C₁₈—OH or the PEG₂PEG₂γE-C₂₀—OH and one of X²¹, X²⁴, X³⁰, or X³¹comprises the -alkyne.

In particular embodiments, the peptide is a GLP-1 analog having the amino acid sequence

(SEQ ID NO: 18)

HGEGTFTSDX¹⁰SSYLEEQAAX²⁰X²¹FIAWLVX²⁸GGGX²⁹,

wherein X¹⁰is Valine, Nle(ε—N₃), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆—N₃, PEG₂-C₅—N₃, or PEG₂PEG₂-C₅—N₃;

X²⁰is Lysine, Nle(ε—N₃), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆—N₃, PEG₂-C₅—N₃, or PEG₂PEG₂-C₅—N₃;

X²¹is glutamic acid, Nle(ε—N₃), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆—N₃, PEG₂-C₅—N₃, or PEG₂PEG₂-C₅—N₃;

X²⁸is Lysine, Nle(ε—N₃), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆—N₃, PEG₂-C₅—N₃, or PEG₂PEG₂-C₅—N₃;

X²⁹Nle(ε—N₃), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆—N₃, PEG₂-C₅—N₃, PEG₂PEG₂-C₅—N₃or absent;

with the proviso that only one of X¹⁰, X²⁰, X²¹, or X²⁸, or X²⁹is Nle(ε—N₃) or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆—N₃, PEG₂-C₅—N₃, PEG₂PEG₂-C₅—N₃.

The peptide may be a GLP-1 analog, for example a GLP(7-37) molecule and analogs thereof comprising 1, 2, 3, 4, 5, or 6 amino acid substitutions or deletions.

In particular embodiments, the peptide is aGLP-1 analog having the amino acid sequence

(SEQ ID NO: 19)

HGEGTFTSDX¹⁰SSYLEEQAAX²⁰X²¹FIAWLVX²⁸GGGX²⁹,

wherein X¹⁰is Valine, Nle(ε-alkyne), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆-alkyne, PEG₂-C₅-alkyne, or PEG₂PEG₂-C₅-alkyne;

X²⁰is Lysine, Nle(ε—N₃), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆-alkyne, PEG₂-C₅-alkyne, or PEG₂PEG₂-C₅-alkyne;

X²¹is glutamic acid, Nle(ε-alkyne), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆-alkyne, PEG₂-C₅-alkyne, or PEG₂PEG₂-C₅-alkyne;

X²⁸is Lysine, Nle(ε-alkyne), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆-alkyne, PEG₂-C₅-alkyne, or PEG₂PEG₂-C₅-alkyne;

X²⁹Nle(ε-alkyne), or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆-alkyne, PEG₂-C₅-alkyne, PEG₂PEG₂-C₅-alkyne or absent;

with the proviso that only one of X¹⁰, X²⁰, X²¹, or X²⁸, or X²⁹is Nle(ε—N₃) or Lysine conjugated via its epsilon amine group to PEG₂PEG₂-γGlu-C₁₆-alkyne, PEG₂-C₅-alkyne, PEG₂PEG₂-C₅-alkyne.

Table 1 shows exemplary peptides comprising an azide group that may be conjugated to an insulin molecule comprising an alkyne group under conditions suitable for the azide group and the alkyne group to form a 1,4-disubstituted 1, 2, 3-triazole.

TABLE 1

SEQ

ID

Peptide
NO:
Sequence

PEP1
35
HsQGTFTSD—K(γEγEC₁₆)SKYLDERAAQ—Nle(εN₃)FVQWLLDT—NH₂

PEP2
36
HUQGTFTSD—K(γEγEC₁₆)SKYLDERAAQDFV—Nle(εN₃)WLLDGRG—NH₂

PEP3
37
HUQGTFTSD—K(γEγEC₁₆)SKYLDURAAQDFV—Nle(εN₃)WL2KGRG—NH₂

PEP4
38
HsQGTFTSD—K(γEγEC₁₆)—SLYLDURAAQDFV—Nle(εN₃)WLLNT—K(γE)—NH₂

PEP5
39
HsQGTFTSD—K(γEγEC₁₆)—SLYLDURAAQDFVQWLLNT—Nle(εN₃)—γE—NH₂

PEP6
40
HUQGTFTSD—K(γEγEC₁₆)SKYLDURRAQDFVQWLLDT—Nle(εN₃)γE—NH₂

PEP7
41
HsQGTFTSD—K(γEγEC₁₆)SKYLDURAAQDFV—Nle(εN₃)—WLLDT—NH₂

PEP8
42
HsQGTFTSD—K(γEγEC₁₆)SSYLDURAAQDFVQWLLNT—Nle(εN₃)—γE—NH₂

PEP9
43
HsQGTFTSD—K(γEγEC₁₆)SSYLDURAAQDFV—Nle(εN₃)—WLLNTKγE—NH₂

PEP10
44
HUQGTFTSD—K(γEγEC₁₆)SKYLDURAAQDFV—Nle(εN₃)—WL2DT—NH₂

PEP11
45
HsQGTFTSD—K(γEγEC₁₆)SKYLDERAAQDFV—Nle(εN₃)—WLLγET—NH₂

PEP12
46
HsQGTFTSD—K(γEγEC₁₆)SKYLDNKRAQDFV—Nle(εN₃)—WLLQT—NH₂

PEP13
47
HsQGTFTSD—K(γEγEC₁₆)SKYLDSRRAHDFV—Nle(εN₃)—WLLNT—NH₂

PEP14
48
HsQGTFTSD—K(γEγEC₁₆)SKYLDERAAQDFV—K(PEG₂—C₅N₃)WLLDT—NH₂

PEP15
49
HsQGTFTSD—K(γEγEC₁₆)SKYLDERAAQDFV—K(PEG₂PEG₂—C₅N₃)—WLLDT—NH₂

PEP16
50
HsQGTFTSD—K(γEγEC₁₆)SKYLDERAA—K(PEG₂—C₅N₃)—DFVQWLLDT—NH₂

PEP17
51
HsQGTFTSD—K(γEγEC₁₆)SKYLDERAA—K(PEG₂PEG₂—C₅N₃)—DFVQWLLDT—NH₂

PEP18
52
HUQGTFTSDYSKYLDURAAQDFVQWLLDTK—Nle(εN₃)—NH₂

PEP19
53
HUQGTFTSD—K(γEγEC₁₆)SKYLDURAAQDFVQWLLDTK—Nle(εN₃)—NH₂

PEP20
54
HUQGTFTSD—K(γEγEC₁₆)SKYLDURAAQDFVQWLLDTK—K(PEG₂—C₅N₃)—NH2

PEP21
55
HUQGTFTSD—K(γEγEC₁₆)SKYLDURAAQDFVQWLLDTK—K(PEG₂PEG₂—C₅N₃)—NH₂

PEP22
56
HUQGTFTSD—K(γEγEC₁₆)SKYLDURAAQDFV—Nle(εN₃)—WLLDTKγE—NH₂

PEP23
57
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQNle(εN₃)FVQWL2DT—NH₂

PEP24
58
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQNle(εN₃)FVQWL2αMDT—NH₂

PEP25
59
HsQGTFTSDYSKYLDERAAQDFV—K(PEG₂PEG₂γE—C₁₆N₃)—WLLDT—NH₂

PEP26
60
HsQGTFTSDYSKYLDERAA—K(PEG₂PEG₂γE—C₁₆N₃)—DFVQWLLDT—NH₂

PEP27
61
HsQGTFTSDYSKYLDERAAQ—K(PEG₂PEG₂γE—C₁₆N₃)—FVQWLLDT—NH₂

PEP28
62
HUQGTFTSDYSKYLDURAAQDFVQWLLDTK—K(PEG₂PEG₂γE—C₁₆N₃)—NH₂

PEP29
63
HsQGTFTSDK(PEG₂PEG₂γEC₁₈—OH)SKYLDERAAQDFVNle(εN₃)WLLDT—NH₂

PEP30
64
HUQGTFTSDYSKYLDARAAK(PEG₂PEG₂γEC18—OH)DFVNle(εN₃)WL2DT—NH₂

PEP31
65
HUQGTFTSDYSKYLDARAAK(PEG₂PEG₂γEC20—OH)DFVNle(εN₃)WL2DT—NH₂

PEP32
66
HsQGTFTSαMDK(γEγEC₁₆)SKYLeuDERAAQDFVNle(εN₃)WL2DT—NH₂

PEP33
67
HsQGTFTSDK(γEγEC₁₆)SKYαMLDERAAQDFVNIe(εN₃)WL2DT—NH₂

PEP34
68
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQαMDFVNle(εN₃)WL2DT—NH₂

PEP35
69
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDαMFVNle(εN₃)WL2DT—NH₂

PEP36
70
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)αMWL2DT—NH₂

PEP37
71
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WαML2DT—NH₂

PEP38
72
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WL2αMDT—NH₂

PEP39
73
HαMSQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFV—Nle(εN₃)—WLLATKγE—NH₂

PEP40
74
HαMsQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFV—Nle(εN₃)—WLLATKγE—NH₂

PEP41
75
HαMSQGTFTSDK(γEγEC₁₆)SKYLDARAAQDFV—Nle(εN₃)—WLLDT—NH₂

PEP42
76
HαMsQGTFTSDK(γEγEC₁₆)SKYLDARAAQDFV—Nle(εN₃)—WLLDT—NH₂

PEP43
77
HαMsVGTFTSDK(γEγEC₁₆)SKYLDURAAQDFV—Nle(εN₃)—WL2DT—NH₂

PEP44
78
HUQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WL2DGRG—NH₂

PEP45
79
HUQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WL2αMDGRG—NH₂

PEP46
80
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVQWLLDTNle(εN₃)γE—NH₂

PEP47
81
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVQWL2DTNle(εN₃)γE—NH₂

PEP48
82
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVQWL2αMDTNle(εN₃)γE—NH₂

PEP49
83
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVNle(εN₃)WL2αMDT—NH₂

PEP50
84
HsEGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WLLDT—NH₂

PEP51
85
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVK(PEG₂PEG₂—C₅N₃)WL2DT—NH₂

PEP52
86
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVK(PEG₂PEG₂—C₅N₃)WL2αMDT—NH₂

PEP53
87
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVK(PEG₂—C₁₀N₃)WLLDT—NH₂

PEP54
88
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVK(PEG₂—C₁₆N₃)WLLDT—NH₂

PEP55
89
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVK(PEG₂—C₅N₃)WL2DT—NH₂

PEP56
90
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVK(PEG₂PEG₂—C₅N₃)WL2DT—NH₂

PEP57
91
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAK(PEG₂PEG₂γE—C₁₀N₃)DFVQWLLDT—NH₂

PEP58
92
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAK(PEG₂PEG₂γE—C₁₆N₃)DFVQWLLDT—NH₂

PEP59
93
HsQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVQWLLDTKNle(εN₃)—NH₂

PEP60
94
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVQWLLDTKNle(εN₃)—NH₂

PEP61
95
HsQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVQWLLDTKK(PEG₂PEG₂—C₅N₃)NH₂

PEP62
96
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVQWLLDTKK(PEG₂PEG₂—C₅N₃)NH₂

PEP63
97
HsQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVNle(εN₃)WLLDTKγE—NH₂

PEP64
98
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVK(PEG₂—C₅N₃)WLLDTKγE—NH₂

PEP65
99
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVK(PEG₂PEG₂—C5N₃)WLLDTKγE—NH₂

PEP66
100
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQK(PEG₂PEG₂γEC₁₆N₃)FVQWLLDT—NH₂

PEP67
101
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVK(PEG₂PEG₂γEC₁₆N₃)WLLDT—NH₂

PEP68
102
HUQGTFTSDKSKYLDURAAQDFVNle(εN₃)WLMNTKQ—COOH

PEP69
103
HsQGTFTSDKSKYLDERAAQDFVNle(εN₃)WLLDT—NH₂

PEP70
104
HUQGTFTSDKSKYLDURAANle(εN₃)DFVQWLMNTKQ—COOH

PEP71
105
HsQGTFTSDKSKYLDERAANle(εN₃)DFVQWLLDT—NH₂

PEP72
106
HUQGTFTSDKSKYLDURAAQDFVQWLMNTKQ Nle(εN₃)—NH₂

PEP73
107
HsQGTFTSDKSKYLDERAAQDFVQWLLDT Nle(εN₃)—NH₂

PEP74
108
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WLLDT—NH₂

PEP75
109
HsEGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WLLDT—NH₂

PEP76
110
HUQGTFTSDK(γEC₁₆)SKYLDERAAQDFVNle(εN₃)WLLDGGPSSGAPPPS—NH₂

PEP77
111
HGEGTFTSDLSKQMEEEAVRLFI Nle(εN₃)WLKNGGPSSGAPPPS—NH₂

PEP78
112
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVKWLLDT—NH₂

PEP79
113
HsQGTFTSDK(γEγEC₁₆)SKYαMLDERAAQDFVNle(εN₃)WL2DT—NH₂

PEP80
114
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)αMWL2DT—NH₂

PEP81
115
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNIe(εN₃)WL2αMDT—NH₂

PEP82
116
HαMSQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFV—Nle(εN₃)WLLATKγE—NH₂

PEP83
117
HαMsQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVNle(εN₃)WLLATKγE—NH₂

PEP84
118
HαMsVGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVNle(εN₃)WL2DT—NH₂

PEP85
119
HαMsQGTFTSDK(γEγEC₁₆)SKYLDARAAQDFVNle(εN₃)WLLDT—NH₂

PEP86
120
HαMSQGTFTSDK(γEγEC₁₆)SKYLDARAAQDFVNle(εN₃)WLLDT—NH₂

PEP87
121
HsEGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WLLDT—NH₂

PEP88
122
HsQGTFTSD—K(γEγEC₁₆)SKYLDERAAQNle(εN₃)FVQWL2DT—NH₂

PEP89
123
HsQGTFTSD—K(γEγEC₁₆)SKYLDERAAQNle(εN₃)FVQWL2αMDT—NH₂

PEP90
124
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVQWL2αMDTNle(εN₃)γE—NH₂

PEP91
125
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVNle(εN₃)WL2αMDT—NH₂

PEP92
126
HUQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WL2DGRG—NH₂

PEP93
127
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVQWLLDTNle(εN₃)γE—NH₂

PEP94
128
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVQWL2DTNle(εN₃)γE—NH₂

PEP95
129
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVK(PEG₂PEG₂—C₅N₃)WL2DT—NH₂

PEP96
130
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVK(PEG₂PEG₂—C₅N₃)WL2αMDT—NH₂

PEP97
131
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVK(PEG₂—C₁₀N₃)WLLDT—NH₂

PEP98
132
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVK(PEG₂—C₁₆N₃)WLLDT—NH₂

PEP99
133
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAK(PEG₂PEG₂γE—C₁₀N₃)DFVQWLLDT—NH₂

PEP100
134
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAK(PEG₂PEG₂γE—C₁₆N₃)DFVQWLLDT—NH₂

PEP101
135
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVpraWLLDT—NH₂

PEP102
136
HsQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVQWLLDTKNle(εN₃)—NH₂

PEP103
137
HsQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVQWLLDTKK(PEG₂PEG₂—C₅N₃)—NH₂

PEP104
138
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQK(PEG₂PEG₂γEC₁₆N₃)FVQWLLDT—NH₂

PEP105
139
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVK(PEG₂PEG₂—C₅N₃)WL2DT—NH₂

PEP106
140
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVQWLLDTKNle(εN₃)—CONH₂

PEP107
141
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVK(PEG₂PEG₂γEC₁₆N₃)WLLDT—NH₂

PEP108
142
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVK(PEG₂—C₅N₃)WL2DT—NH₂

PEP109
143
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVQWLLDTKK(PEG₂PEG₂—C₅N₃)CONH₂

PEP110
144
HsQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVNle(εN₃)WLLDTKγE—NH₂

PEP111
145
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVK(PEG₂PEG₂—C₅N₃)WLLDTKγE—NH₂

PEP112
146
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVK(PEG₂—C₅N₃)WLLDTKγE—NH₂

PEP113
147
HsQGTFTSDK(γEγEC₁₆)SKYLDSRAAQDFVNle(εN₃)WLLDT—NH₂

PEP114
148
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WLLγET—NH₂

PEP115
149
HsQGTFTSDK(γEγEC₁₆)SKYLDNKRAQDFVNle(εN₃)WLMQT—NH₂

PEP116
150
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVNle(εN₃)WL2γET—NH₂

PEP117
151
HUQGTFVSDK(γEγEC₁₆)SKYLDURAAQDFVNle(εN₃)WL2ET—NH₂

PEP118
152
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVNle(εN₃)WLLdTKγE—NH₂

PEP119
153
HUQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)αMWL2DT—NH₂

PEP120
154
HUQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WL2αMDT—NH₂

PEP121
155
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVNle(εN₃)αMWL2DT—NH₂

PEP122
156
HUQGTFTSDK(γEγEC₁₆)SKYLDURAAQDFVNle(εN₃)WL2αMDT—NH₂

PEP123
157
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVQWLZαMDTKNle(εN₃)—NH₂

PEP124
158
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVQαMWL2DTKNle(εN₃)—NH₂

PEP125
159
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVQαMWL2DTKK(PEG₂PEG₂C₅N₃)—NH₂

PEP126
160
HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVQWL2αMDTKK(PEG₂PEG2C₅N₃)—NH₂

PEP127
161
HUQGTFTSDYSKYLDARAAK(PEG₂PEG₂γEC₁₈OH)DFVQWL2DTKNle(εN3)—NH₂

PEP128
162
HsQGTFTSDK(PEG₂PEG_2γEC₁₈OH)SKYLDERAAQDFVQWLLDTKNle(εN₃)—NH₂

PEP129
163
HUQGTFTSDYSKYLDARAAK(PEG₂PEG₂γEC₁₈OH)DFVNle(εN₃)WL2αMDT—NH₂

PEP130
164
HUQGTFTSDYSKYLDARAAK(PEG₂PEG₂γEC₁₈OH)DFVK(PEG₂PEG₂C₁₆N₃)WL2αMDT—NH₂

PEP131
165
HUQGTFTSαMDK(γEγEC₁₆)SKYLDERAAQDFVNle(εN₃)WL2DT—NH₂

PEP132
166
HUQGTFTSαMDK(γEγEC₁₆)SKYLDERAAQDFVK(PEG₂PEG₂C₁₆N₃)WL2DT—NH₂

Table legend:

U = aminoisobutyric acid;

γE = γ-glutamic acid;

2 = L-methionine sulphone;

αMD = alpha-Methyl-L-Aspartic acid;

αML = alpha-Methyl-L-leucine;

αMF = alpha-Methyl-L-phenylalanine;

αMW = alpha-Methyl-L-tryptophan;

s = D-serine;

αMS = alpha-Methyl-L-Serine;

αMs = alpha-Methyl-D-Serine;

Nle(εN₃) = ε-azidonorleucine;

PEG₂= 8-amino-3,6-dioxaoctanoic acid;

C₅N₃= 5-azido pentinoic acid;

C₁₀N₃= 10-azido-decanoic acid;

C₁₆N₃= 16-azido-hexadecanoic acid;

C₁₈—OH = —CO—(CH₂)₁₆—COOH;

C₂₀—OH = —CO—(CH₂)₁₈—COOH;

NH₂= C-terminal amide;

pra = propargyl glycine

embedded image

The peptide disclosed herein may have anywhere from at least about 1% (including at least about 1.5%, 2%, 5%, 7%, 10%, 20%, 30%, 40%, 50%, 60%, 75%, 100%, 125%, 150%, 175%) to about 200% or higher activity at the GLP-1 receptor relative to native GLP-1 and anywhere from 5 at least about 1% (including about 1.5%, 2%, 5%, 7%, 10%, 20%, 30%, 40%, 50%, 60%, 75%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 350%, 400%, 450%) to about 500% or higher activity at the glucagon receptor relative to native glucagon. In some embodiments, the peptides described herein exhibit no more than about 100%, 1000%, 10,000%, 100,000%, or 1,000,000% of the activity of native glucagon at the glucagon receptor. In some embodiments, the peptides described herein exhibit no more than about 100%, 1000%, 10,000%, 100,000%, or 1,000,000% of the activity of native GLP-1 at the GLP-1 receptor. In exemplary embodiments, a peptide may exhibit at least 10% of the activity of native glucagon at the glucagon receptor and at least 50% of the activity of native GLP-1 at the GLP-1 receptor, or at least 40% of the activity of native glucagon at the glucagon receptor and at least 40% of the activity of native GLP-1 at the GLP-1 receptor, or at least 60% of the activity of native glucagon at the glucagon receptor and at least 60% of the activity of native GLP-1 at the GLP-1 receptor.

Selectivity of a peptide for the glucagon receptor versus the GLP-1 receptor can be described as the relative ratio of glucagon/GLP-1 activity (the peptide analog's activity at the glucagon receptor relative to native glucagon, divided by the peptide's activity at the GLP-1 receptor relative to native GLP-1). For example, a peptide that exhibits 60% of the activity of native glucagon at the glucagon receptor and 60% of the activity of native GLP-1 at the GLP-1 receptor has a 1:1 ratio of glucagon/GLP-1 activity. Exemplary ratios of glucagon/GLP-1 activity include about 1:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1, or about 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, or 1:1.5. As an example, a glucagon/GLP-1 activity ratio of 10:1 indicates a 10-fold selectivity for the glucagon receptor versus the GLP-1 receptor. Similarly, a GLP-1/glucagon activity ratio of 10:1 indicates a 10-fold selectivity for the GLP-1 receptor versus the glucagon receptor.

Insulin Molecules

The insulin molecule comprising the conjugates disclosed herein encompasses all salt and non-salt forms of the insulin molecule. It will be appreciated that the salt form may be anionic or cationic depending on the insulin molecule. The term “insulin” or “an insulin molecule” is intended to encompass both wild-type insulin and modified forms of insulin as long as they are bioactive (i.e., capable of causing a detectable reduction in glucose when administered in vivo). Wild-type insulin includes insulin from any species whether in purified, synthetic or recombinant form (e.g., human insulin, porcine insulin, bovine insulin, rabbit insulin, sheep insulin, etc.). A number of these are available commercially, e.g., from Sigma-Aldrich (St. Louis, Mo.). A variety of modified forms of insulin are known in the art (e.g. see Crotty and Reynolds, Pediatr. Emerg. Care. 23:903-905, 2007 and Gerich, Am. J Med. 113:308-16, 2002 and references cited therein). Modified forms of insulin (insulin analogs) may be chemically modified (e.g., by addition of a chemical moiety such as a PEG group or a fatty acyl chain as described below) and/or mutated (i.e., by addition, deletion or substitution of one or more amino acids).

In particular embodiments, an insulin molecule comprising the conjugate may be wild-type human recombinant insulin or may differ from a wild-type insulin by 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-9, 3-8, 3-7, 3-6, 3-5, 3- 4, 4-9, 4-8, 4-7, 4-6, 4-5, 5-9, 5-8, 5-7, 5-6, 6-9, 6-8, 6-7, 7-9, 7-8, 8-9, 9, 8, 7, 6, 5, 4, 3, 2 or 1) amino acid substitutions, additions and/or deletions. In particular embodiments, an insulin molecule of the present disclosure will differ from wild-type insulin by amino acid substitutions only. In particular embodiments, an insulin molecule of the present disclosure will differ from wild-type insulin by amino acid additions only. In particular embodiments, an insulin molecule of the present disclosure will differ from wild-type insulin by both amino acid substitutions and additions. In particular embodiments, an insulin molecule of the present disclosure will differ from a wild-type insulin by both amino acid substitutions and deletions.

In particular embodiments, amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. In particular embodiments, a substitution may be conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and tyrosine, phenylalanine. In particular embodiments, the hydrophobic index of amino acids may be considered in choosing suitable mutations. The importance of the hydrophobic amino acid index in conferring interactive biological function on a peptide is generally understood in the art. Alternatively, the substitution of like amino acids can be made effectively on the basis of hydrophilicity. The importance of hydrophilicity in conferring interactive biological function of a peptide or peptide is generally understood in the art. The use of the hydrophobic index or hydrophilicity in designing peptides is further discussed in U.S. Pat. No. 5,691,198.

The wild-type sequence of recombinant human insulin (A-chain and B-chain) is shown in Table 2 below. In various embodiments, an insulin molecule of the present disclosure is mutated at the B28 and/or B29 positions of the B-peptide sequence. For example, insulin lispro (HUMALOG®) is a rapid acting insulin mutant in which the penultimate lysine and proline residues on the C-terminal end of the B-peptide have been reversed (Lys^B28Pro^B29-human insulin) (SEQ ID NO:22). This modification blocks the formation of insulin multimers. Insulin aspart (NOVOLOG®) is another rapid acting insulin mutant in which proline at position B28 has been substituted with aspartic acid (AspB²⁸-human insulin) (SEQ ID NO:23). This mutant also prevents the formation of multimers. In some embodiments, mutation at positions B28 and/or B29 is accompanied by one or more mutations elsewhere in the insulin peptide. For example, insulin glulisine (APIDRA®) is yet another rapid acting insulin mutant in which aspartic acid at position B3 has been replaced by a lysine residue and lysine at position B29 has been replaced with a glutamic acid residue (Lys^B3Glu^B29-human insulin) (SEQ ID NO:24).

TABLE 2

SEQ ID

NO:
Description
Sequence

20
Human insulin A chain
GIVEQCCTSICSLYQLENYCN

21
Human insulin B chain
FVNQHLCGSHLVEALYLVCGERGFFYTPKT

22
Insulin lispro B chain
FVNQHLCGSHLVEALYLVCGERGFFYTKPT

23
Insulin aspart B chain
FVNQHLCGSHLVEALYLVCGERGFFYTDKT

24
Insulin glusiline B
FVKQHLCGSHLVEALYLVCGERGFFYTPET

chain

25
Insulin glargine A chain
GIVEQCCTSICSLYQLENYCG

26
Insulin glargine B chain
FVNQHLCGSHLVEALYLVCGERGFFYTPKT

RR

In various embodiments, the insulin molecule comprising the conjugate may have an isoelectric point that is shifted relative to human insulin. In some embodiments, the shift in isoelectric point is achieved by adding one or more arginine residues to the N-terminus of the insulin A-peptide and/or the C-terminus of the insulin B-peptide. Examples of such insulin peptides include Arg^A0-human insulin, Arg^B31Arg^B32-human insulin, Gly^A21Arg^B31Arg^B32-human insulin, Arg^A0Arg^B31Arg^B32-human insulin, and Arg^A0Gly^A21Arg^B31Arg^B32-human insulin. By way of further example, insulin glargine (LANTUS®) is an exemplary long acting insulin mutant in which Asp^A21has been replaced by glycine (SEQ ID NO:25), and two arginine residues have been added to the C-terminus of the B-peptide (SEQ ID NO:26). The effect of these changes is to shift the isoelectric point, producing a solution that is completely soluble at pH 4. Thus, in some embodiments, an insulin molecule of the present disclosure comprises an A-peptide sequence wherein A21 is Gly and B-peptide sequence wherein B31 and B32 are Arg-Arg. It is to be understood that the present disclosure encompasses all single and multiple combinations of these mutations and any other mutations that are described herein (e.g., Gly^A21-human insulin, Gly^A21Arg^B31-human insulin, Arg^B31Arg^B32-human insulin, Arg^B31-human insulin).

In various embodiments, the insulin molecule comprising the conjugate may be truncated. For example, in particular embodiments, a B-peptide sequence of an insulin peptide of the present disclosure is missing B1, B2, B3, B26, B27, B28, B29 and/or B30. In particular embodiments, combinations of residues are missing from the B-peptide sequence of an insulin peptide of the present disclosure. For example, the B-peptide sequence may be missing residues B(1-2), B(1-3), B(29-30), B(28-30), B(27-30) and/or B(26-30). In some embodiments, these deletions and/or truncations apply to any of the aforementioned insulin molecules (e.g., without limitation to produce des(B30)-insulin lispro, des(B30)-insulin aspart, des(B30)-insulin glulisine, des(B30)-insulin glargine, etc.).

In some embodiments, the insulin molecule may comprise additional amino acid residues on the N- or C-terminus of the A or B-peptide sequences. In some embodiments, one or more amino acid residues are located at positions A0, A21, B0 and/or B31. In some embodiments, one or more amino acid residues are located at position A0. In some embodiments, one or more amino acid residues are located at position A21. In some embodiments, one or more amino acid residues are located at position B0. In some embodiments, one or more amino acid residues are located at position B31. In particular embodiments, an insulin molecule does not include any additional amino acid residues at positions A0, A21, B0 or B31.

In particular embodiments, the insulin molecule comprising the conjugate may be mutated such that one or more amidated amino acids are replaced with acidic forms. For example, asparagine may be replaced with aspartic acid or glutamic acid. Likewise, glutamine may be replaced with aspartic acid or glutamic acid. In particular, Asn^A18, Asn^A21, or Asn^B3, or any combination of those residues, may be replaced by aspartic acid or glutamic acid. Gln^A15or Gln^B4, or both, may be replaced by aspartic acid or glutamic acid. In particular embodiments, an insulin molecule has aspartic acid at position A21 or aspartic acid at position B3, or both.

One skilled in the art will recognize that it is possible to mutate yet other amino acids in the insulin molecule while retaining biological activity. For example, without limitation, the following modifications are also widely accepted in the art: replacement of the histidine residue of position B10 with aspartic acid (His^B10→Asp^B10); replacement of the phenylalanine residue at position B1 with aspartic acid (Phe^B1→Asp^B1); replacement of the threonine residue at position B30 with alanine (Thr^B30→Ala^B30); replacement of the tyrosine residue at position B26 with alanine (Tyr^B26→Ala^B26); and replacement of the serine residue at position B9 with aspartic acid (Ser^B9→Asp^B9).

In various embodiments, the insulin molecule comprising the conjugate may have a protracted profile of action. Thus, in particular embodiments, an insulin molecule of the present disclosure may be acylated with a fatty acid. That is, an amide bond is formed between an amino group on the insulin molecule and the carboxylic acid group of the fatty acid. The amino group may be the alpha-amino group of an N-terminal amino acid of the insulin molecule, or may be the epsilon-amino group of a lysine residue of the insulin molecule. An insulin molecule of the present disclosure may be acylated at one or more of the three amino groups that are present in wild-type human insulin or may be acylated on lysine residue that has been introduced into the wild-type human insulin sequence. In particular embodiments, an insulin molecule may be acylated at position B1. In particular embodiments, an insulin molecule may be acylated at position B29. In particular embodiments, the fatty acid is selected from myristic acid (C₁₄), pentadecylic acid (C₁₅), palmitic acid (C₁₆), heptadecylic acid (C₁₇) and stearic acid (C₁₈). For example, insulin detemir (LEVEMIR®) is a long acting insulin mutant in which Thr^B30has been deleted, and a C₁₄fatty acid chain (myristic acid) has been attached to Lys^B29.

In some embodiments, the N-terminus of the A-peptide, the N-terminus of the B-peptide, the epsilon-amino group of Lys at position B29 or any other available amino group in an insulin molecule of the present disclosure is covalently linked to a fatty acid moiety of general formula:

embedded image

wherein R^Fis hydrogen or a C_1-30alkyl group. In some embodiments, R^Fis a C_1-20alkyl group, a C_3-19alkyl group, a C_5-18alkyl group, a C_6-17alkyl group, a C_8-16alkyl group, a C_10-15alkyl group, or a C_12-14alkyl group. In particular embodiments, the insulin molecule is conjugated to the moiety at the A1 position. In particular embodiments, the insulin molecule is conjugated to the moiety at the B1 position. In particular embodiments, the insulin molecule is conjugated to the moiety at the epsilon-amino group of Lys at position B29. In particular embodiments, position B28 of the insulin molecule is Lys and the epsilon-amino group of Lys^B28is conjugated to the fatty acid moiety. In particular embodiments, position B3 of the insulin molecule is Lys and the epsilon-amino group of Lys^B3is conjugated to the fatty acid moiety. In some embodiments, the fatty acid chain is 8-20 carbons long. In some embodiments, the fatty acid is octanoic acid (C8), nonanoic acid (C9), decanoic acid (C10), undecanoic acid (C11), dodecanoic acid (C12), or tridecanoic acid (C13). In particular embodiments, the fatty acid is myristic acid (C14), pentadecanoic acid (C15), palmitic acid (C16), heptadecanoic acid (C17), stearic acid (C18), nonadecanoic acid (C19), or arachidic acid (C20).

In various embodiments, the insulin molecule comprising the conjugate may have the three wild-type disulfide bridges (i.e., one between position 7 of the A-chain peptide and position 7 of the B-chain peptide, a second between position 20 of the A-chain peptide and position 19 of the B-chain peptide, and a third between positions 6 and 11 of the A-chain peptide). In particular embodiments, an insulin molecule is mutated such that the site of mutation is used as a conjugation point, and conjugation at the mutated site reduces binding to the insulin receptor (e.g., Lys^A3). In particular other embodiments, conjugation at an existing wild-type amino acid or terminus reduces binding to the insulin receptor (e.g., Gly^A1). In some embodiments, an insulin molecule is conjugated at position A4, A5, A8, A9, or B30. In particular embodiments, the conjugation at position A4, A5, A8, A9, or B30 takes place via a wild-type amino acid side chain (e.g., Glu^A4). In particular other embodiments, an insulin molecule is mutated at position A4, A5, A8, A9, or B30 to provide a site for conjugation (e.g., Lys^A4, Lys^A5, Lys^A8, Lys^A9, or Lys^B330).

In particular embodiments, the insulin molecule comprising the conjugate may have an A chain sequence comprising a sequence of GIVEQCCXISICSLYQLENYCX₂(SEQ ID NO: 27); and a B chain sequence comprising a sequence of X₃LCGX₄X₅LVEALYLVCG ERGFF (SEQ ID NO: 28) or X₈VNQX₃LCGX₄X₅LVEALYLVCGERGFFYTX₆X₇(SEQ ID NO: 29) wherein

X₁is selected from the group consisting of threonine and histidine;

X₂is asparagine or glycine;

X₃is selected from the group consisting of histidine and threonine;

X₄is selected from the group consisting of alanine, glycine and serine;

X₅is selected from the group consisting of histidine, aspartic acid, glutamic acid, homocysteic acid and cysteic acid;

X₆is aspartate-lysine dipeptide, a lysine-proline dipeptide, or a proline-lysine dipeptide;

X₇is threonine, alanine, or a threonine-arginine-arginine tripeptide; and

X₈is selected from the group consisting of phenylalanine and desamino-phenylalanine. In particular embodiments, the insulin is conjugated to an alkyne-C₂-C₁₆acyl, alkyne-PEG_nwherein n is 1-50, or alkyne-(PEG₂)_nwherein n is 1-20 or the one Lysine is conjugated to an azide-C₂-C₁₆acyl, azide-PEG_nwherein n is 1-50, or azide-(PEG₂)_nwherein n is 1-20 with the proviso that one of R1, R2, or R3 is alkyne —C₂-C₁₆acyl, azide-PEG_nwherein n is 1-50, or azide-(PEG₂)_nwherein n is 1-20.

In particular embodiments, the A-chain may have the amino acid sequence set forth in SEQ ID NO:20 or SEQ ID NO:25 and the B-chain may have the amino acid sequence set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24. In particular embodiments, the A-chain may have the amino acid sequence set forth in SEQ ID NO:25 and the B-chain may have the amino acid sequence set forth in SEQ ID NO:26. In particular embodiments, the insulin analog is a desB30 insulin analog, a des B29-B30 insulin analog, a des B28-B30 insulin analog, a des B27-B30 insulin analog or a des B26-B30 insulin analog.

In any one of the above embodiments, at least one amino group of the insulin molecule is conjugated to a linker comprising a terminal azide group or alkyne group. The amino group may be at the A1 position, the B1 position, or an epsilon amino group of a lysine residue on the A chain or the B chain. In particular embodiments, the lysine residue is at the B29 position of the B chain. In particular embodiments, the lysine residue is at the B28 position of the B chain, for example, insulin lispro has a lysine at the B28 position. In particular embodiments, the lysine residue is at the B3 position of the B chain, for example, insulin glulisine has a lysine at the B3 position. In particular embodiments, the epsilon amine of the lysine residue is converted to an azide group, which provides a norleucine with an epsilon azide group.

In particular embodiments, the insulin molecule comprising the conjugate has an A chain peptide sequence comprising a sequence of X₁I X₂E X₃CCX₄X₅X₆CS X₇X₈X₉LE X₁₀YC X₁₁X₁₂(SEQ ID NO:30); and a B chain peptide sequence comprising a sequence of X₁₃VX₁₄X₁₅HLCGSHLVEALX₁₆X₁₇VCGERGFX₁₈YTX₁₉X₂₀X₂₁X₂₂X₂₃X₂₄X₂₅X₂₆(SEQ ID NO:31) wherein

X₁is glycine (G) or lysine (K);

X₂is valine (V), glycine (G), or lysine (K);

X₃is glutamine (Q) or lysine (K);

X₄is threonine (T) or histidine (H);

X₅is serine (S) or lysine (K);

X₆is isoleucine (I) or lysine;

X₇is leucine (L) or lysine (K);

X₈is tyrosine (Y) or lysine (K);

X₉is glutamine (Q) or lysine (K);

X₁₀is asparagine (N) or lysine (K);

X₁₁is asparagine (N) or glycine (G);

X₁₂is arginine (R), lysine (K) or absent;

X₁₃is phenylalanine (F) or lysine (K);

X₁₄is asparagine (N) or lysine (K);

X₁₅is glutamine (Q) or lysine (K);

X₁₆is tyrosine (Y) or lysine (K);

X₁₇is leucine (L) or lysine (K);

X₁₈is phenylalanine (F) or lysine (K);

X₁₉is proline (P) or lysine (K);

X₂₀is lysine (K) or proline (P);

X₂₁is threonine (T) or absent;

X₂₂is arginine (R) if X₂₁is threonine (T), or absent;

X₂₃is proline (P) if X₂₂is arginine (R), or absent;

X₂₄is arginine (R) if X₂₃is proline (P), or absent;

X₂₅is proline (P) if X₂₄is arginine (R), or absent; and

X₂₆is arginine (R) if X₂₅is proline (P), or absent,

With the proviso that at least one of X₁, X₂, X₃, X₅, X₆, X₇, X₈, X₉, X₁₀, X₁₂, X₁₃, X₁₄, X₁₅, X₁₆, X₁₇, X₁₈, X₁₉, or X₂₀is a lysine (K) wherein when X₂₀is a lysine (K) then X₂₁is absent or if X₂₁is present then at least one of X₁, X₂, X₃, X₄, X₅, X₆, X₇, X₈, X₉, X₁₀, X₁₁, X₁₂, X₁₃, X₁₄, X₁₅, X₁₆, X₁₇is lysine (K), or X₄is histidine (H), or X₁₁is glycine (G); or at least one of X₁₂or X₂₂is present. In particular aspects, if X₁, X₂, X₃, X₅, X₆, X₇, X₈, X₉, X₁₀, X₁₂, X₁₃, X₁₄, X₁₅, X₁₆, X₁₇, X₁₈, or X₁₉is a lysine (K) then X₂₀is not a lysine (K); and with the proviso that at least one Lysine (K) is conjugated to a linker having a terminal alkyne or azide group or the epsilon amine of at least one lysine residue is converted to an azide group, which provides a norleucine with an epsilon azide group.

In particular embodiments, the insulin molecule comprising the conjugate may be a desB30 human insulin analog, which may comprise an A chain peptide sequence comprising a sequence of X₁I X₂E X₃CCX₄X₅X₆CS X₇X₈X₉LE X₁₀YC X₁₁X₁₂(SEQ ID NO:30); and a B chain peptide sequence comprising a sequence of X₁₃VX₁₄X₁₅HLCGSHLVEALX₁₆X₁₇VCGERGFX₁₈YTX₁₉X₂₀(SEQ ID NO:32) wherein

X₁is glycine (G) or lysine (K);

X₂is valine (V), glycine (G), or lysine (K);

X₃is glutamine (Q) or lysine (K);

X₄is threonine (T) or histidine (H);

X₅is serine (S) or lysine (K);

X₆is isoleucine (I) or lysine;

X₇is leucine (L) or lysine (K);

X₈is tyrosine (Y) or lysine (K);

X₉is glutamine (Q) or lysine (K);

X₁₀is asparagine (N) or lysine (K);

X₁₁is asparagine (N) or glycine (G);

X₁₂is arginine (R), lysine (K) or absent;

X₁₃is phenylalanine (F) or lysine (K);

X₁₄is asparagine (N) or lysine (K);

X₁₅is glutamine (Q) or lysine (K);

X₁₆is tyrosine (Y) or lysine (K);

X₁₇is leucine (L) or lysine (K);

X₁₈is phenylalanine (F) or lysine (K);

X₁₉is proline (P) or lysine (K);

X₂₀is lysine (K) or proline (P);

With the proviso that at least one of X₁, X₂, X₃, X₅, X₆, X₇, X₈, X₉, X₁₀, X₁₂, X₁₃, X₁₄, X₁₅, X₁₆, X₁₇, X₁₈, X₁₉, or X₂₀is a lysine (K); and with the proviso that at least one Lysine (K) is conjugated to a linker having a terminal alkyne or azide group or the epsilon amine of at least one lysine residue is converted to an azide group, which provides a norleucine with an epsilon azide group.

In particular embodiments, the insulin molecule comprising the conjugate may comprise an A chain peptide sequence comprising a sequence of X₁I X₂E X₃CCX₄X₅X₆CS X₇X₈X₉LE X₁₀YC X₁₁X₁₂(SEQ ID NO:30); and a B chain peptide sequence comprising a sequence of X₁₃VX₁₄X₁₅HLCGSHLVEALX₁₆X₁₇VCGERGFX₁₈YTX₁₉X₂₀TRPRPR (SEQ ID NO:33) wherein

X₁is glycine (G) or lysine (K);

X₂is valine (V), glycine (G), or lysine (K);

X₃is glutamine (Q) or lysine (K);

X₄is threonine (T) or histidine (H);

X₅is serine (S) or lysine (K);

X₆is isoleucine (I) or lysine;

X₇is leucine (L) or lysine (K);

X₈is tyrosine (Y) or lysine (K);

X₉is glutamine (Q) or lysine (K);

X₁₀is asparagine (N) or lysine (K);

X₁₁is asparagine (N) or glycine (G);

X₁₂is arginine (R), lysine (K) or absent;

X₁₃is phenylalanine (F) or lysine (K);

X₁₄is asparagine (N) or lysine (K);

X₁₅is glutamine (Q) or lysine (K);

X₁₆is tyrosine (Y) or lysine (K);

X₁₇is leucine (L) or lysine (K);

X₁₈is phenylalanine (F) or lysine (K);

X¹⁹is proline (P) or lysine (K);

X₂₀is lysine (K) or proline (P);

with the proviso that at least one of X₁, X₂, X₃, X₅, X₆, X₇, X₈, X₉, X₁₀, X₁₂, X₁₃, X₁₄, X₁₅, X₁₆, X₁₇, X₁₈, X₁₉, or X₂₀is a lysine (K); and with the proviso that at least one Lysine (K) is conjugated to a linker having a terminal alkyne or azide group or the epsilon amine of at least one lysine residue is converted to an azide group, which provides a norleucine with an epsilon azide group.

In particular embodiments, the insulin molecule comprising the conjugate may have an A chain peptide sequence comprising a sequence of X₁I X₂E X₃CCX₄X₅X₆CS X₇X₈X₉LE X₁₀YC X₁₁X₁₂(SEQ ID NO: 30); and a B chain peptide sequence comprising a sequence of X₁₃VX₁₄X₁₅HLCGSHLVEALX₁₆X₁₇VCGERGFX₁₈YTX₁₉X₂₀TRPR (SEQ ID NO: 34) wherein

X₁is glycine (G) or lysine (K);

X₂is valine (V), glycine (G), or lysine (K);

X₃is glutamine (Q) or lysine (K);

X₄is threonine (T) or histidine (H);

X₅is seine (S) or lysine (K);

X₆is isoleucine (I) or lysine;

X₇is leucine (L) or lysine (K);

X₈is tyrosine (Y) or lysine (K);

X₉is glutamine (Q) or lysine (K);

X₁₀is asparagine (N) or lysine (K);

X₁₁is asparagine (N) or glycine (G);

X₁₂is arginine (R), lysine (K) or absent;

X₁₃is phenylalanine (F) or lysine (K);

X₁₄is asparagine (N) or lysine (K);

X₁₅is glutamine (Q) or lysine (K);

X₁₆is tyrosine (Y) or lysine (K);

X₁₇is leucine (L) or lysine (K);

X₁₈is phenylalanine (F) or lysine (K);

X¹⁹is proline (P) or lysine (K);

X₂₀is lysine (K) or proline (P);

The following structure represents human insulin (e.g., recombinant human insulin (RHI)) or any insulin analog disclosed herein

embedded image

wherein the insulin is a heterodimer in which the cysteine residues a positions 6 and 11 of the A chain are linked in a disulfide bond, the cysteine residues at position 7 of the A chain and position 7 of the B chain are linked in a disulfide bond, and the cysteine residues at position 20 of the A chain and 19 of the B chain are linked in a disulfide bond and wherein A1 is the amino acid at position 1 of the A chain peptide, B1 is the amino acid at position 1 of the B chain peptide, and K is a lysine, which may be in any position in the insulin or insulin analog. In particular embodiments, the lysine is at position B29, B28, or B3. In particular embodiments, the lysine is at position B29 and is represented by the structure

embedded image

In particular embodiments, the lysine is at position B28 and is represented by the structure.

embedded image

In particular embodiments, the lysine is at position B3 and is represented by the structure

embedded image

Unless otherwise indicated, the term “insulin” is used to indicate the insulin is a human insulin in which the A chain has amino acid sequence GIVEQCCTSICSLYQLENYCN (SEQ ID NO:20) and the B chain has amino acid sequence FVNQHLCGSHLVEALYLVCGERGFFYTPKT (SEQ ID NO:21).

The following structure represents a single-chain insulin analog (SCI) in which the C-terminal amino acid of the B chain is covalently linked the N-terminal amino acid of the A chain by a non-peptide linker or a peptide linker comprising three to 35 amino acids

embedded image

wherein the cysteine residues a positions 6 and 11 of the A chain are linked in a disulfide bond, the cysteine residues at position 7 of the A chain and position 7 of the B chain are linked in a disulfide bond, and the cysteine residues at position 20 of the A chain and 19 of the B chain are linked in a disulfide bond and wherein B1 is the amino acid at position 1 of the B chain peptide and K is a lysine, which may be in any position in the insulin or insulin analog. In particular embodiments, the lysine is at position B29, B28, or B3. In particular embodiments, the lysine is at position B29 and is represented by the structure

embedded image

In particular embodiments, the lysine is at position B28 and is represented by the structure

embedded image

In particular embodiments, the lysine is at position B3 and is represented by the structure

embedded image

Unless otherwise indicated, the term “SCI” is used to indicate the single-chain insulin an A chain having an amino acid sequence GIVEQCCTSICSLYQLENYCN (SEQ ID NO:20) and a B chain having the amino acid sequence FVNQHLCGSHLVEALYLVCGERGFFYTPKT (SEQ ID NO:21).

Single-chain insulins and analogs thereof have been disclosed in U.S. Pat. No. 8,940,860, which is incorporated herein by reference in its entirety and U.S. Publications US 20150374795 and US 20150299285, which are incorporated herein by reference in their entirety.

Linkers

The linker conjugated to the insulin or the insulin may be any non-peptide linker comprising a terminal azide group or a terminal alkyne group with the proviso that when the incretin is conjugated to a linker comprising an azide group then the insulin is conjugated to a linker comprising an alkyne group and when the incretin is conjugated to a linker comprising an azide group then the insulin is conjugated to a linker comprising an alkyne group.

The non-peptide linker may comprise a C₁-C₅₀hydrocarbon chain or substituted hydrocarbon chain, a PEG_nwherein n is 1-50, a (PEG₂)_nwherein n is 1-50, a (PEG₂)_n-(γGlu)_p-C_nwherein each n is independently 1-50 and p is 1 or 2, a (PEG₂)_n-C_nwherein each n is independently is 1-50, a (PEG)_n(PEG)_nwherein each n is independently 1-50, a (PEG)_n(PEG)_n(PEG)_nwherein each n is independently 1-50a PEG_n-(Lys-(γGlu)_p-C_n)—C_nwherein each n is independently 1-50 and p is 1 or 2, and a C₅-Lys(γE-C_n)-PEG_nwherein each n is independently 1-50.

In particular embodiments, the linker may be a propargyl-polyethylene glycol (PEG) linker having the general formula

embedded image

wherein n is 0-50 and the wavy line indicates the bond between the linker and an amino group on the insulin molecule or analog or an amino group on the incretin peptide. In particular embodiments n is 1-25. In particular embodiments, the linker may be selected from the group

embedded image

In particular embodiments, the linker may be a propargyl-C₅-(polyethylene glycol 2)_n((PEG₂)_n) linker having the general formula

embedded image

wherein n is 1-50 and the wavy line indicates the bond between the linker and an amino group on the insulin molecule or analog or an amino group on the incretin peptide. In particular embodiments n is 1-5. In particular embodiments, the linker may be selected from the group

embedded image

In particular embodiments, the linker may be a propargyl-C₅-Lys(γE-C_n)-PEG_nlinker having the general formula

embedded image

wherein each n is independently 1-50 and the wavy line indicates the bond between the linker and an amino group on the insulin molecule or analog or an amino group on the incretin peptide. In particular embodiments, the linker has the formula

embedded image

In particular embodiments, the linker may be a propargyl-(PEG_n)(PEG_n) linker having the general formula

embedded image

wherein each n is independently 0-50 and the wavy line indicates the bond between the linker and an amino group on the insulin molecule or analog or an amino group on the incretin peptide. In particular embodiments, the linker is selected from

embedded image

In particular embodiments, the linker may be an propargyl-(PEG_n)(PEG_n)(PEG_n) linker having the general formula

embedded image

In particular embodiments, the linker may be a propargyl-C_nhaving the general formula

embedded image

In particular embodiments, the linker may be a BCN-PEG₄(endo) linker having the general formula

embedded image

In particular embodiments, the linker may be a propargyl-phenylacetate linker having the general formula

embedded image

wherein the wavy line indicates the bond between the linker and an amino group on the insulin molecule or analog or an amino group on the incretin peptide. In particular embodiments, the linker is selected from

embedded image

In particular embodiments, the linker may be an azido-polyethylene glycol (PEG) linker having the general formula

embedded image

In particular embodiments, the linker may be an azido-C₅-Lys(γE-C_n)-PEG_nlinker having the general formula

embedded image

In particular embodiments, the linker may be an azido-(PEG_n)(PEG_n) linker having the general formula

embedded image

In particular embodiments, the linker may be an azido-(PEG_n)(PEG_n)(PEG_n) linker having the general formula

embedded image

In particular embodiments, the linker may be an azido-C_nhaving the general formula

embedded image

In particular embodiments, the linker may be an azido-phenylacetate linker having the general formula

embedded image

In particular embodiments, the linker may be an azido-C_n-(PEG₂)_nlinker having the general formula

embedded image

wherein each n is independently 1-10 and the wavy line indicates the bond between the linker and an amino group on the insulin molecule or analog or an amino group on the incretin peptide.

In particular embodiments, C_nis C₅and the linker may be selected from the group

embedded image

In particular embodiments, C_nis C₁₀and the linker may be selected from the group

embedded image

In particular embodiments, C_nis C₁₆and the linker may be selected from the group

embedded image

In particular embodiments, the linker may be an azido-C_n-γE-(PEG₂)_n-linker having the general formula

embedded image

wherein each n is independently 1-10 and the wavy line indicates the bond between the linker and an amino group on the insulin molecule or analog or an amino group on the incretin peptide. In particular embodiments, C_nis C₁₆and the linker may be selected from the group

embedded image

In particular embodiments, C_nis C₁₀and the linker may be selected from the group

embedded image

In particular embodiments, the linker may be azido-norleucine having the structure

embedded image

wherein the wavy lines indicate the bonds between the azido-norleucine and adjacent amino acids in either the insulin molecule or the incretin peptide.

In particular embodiments, the linking moiety conjugating the insulin molecule to the incretin peptide comprises the formula

embedded image

Exemplary linking moieties are shown in Table 3. For structures 1-25, the wavy line on the left indicates the bond between alpha and beta carbons of Norleucine (Nle) or Lysine (Lys or K) and the wavy line on the right indicates the bond between the CO and an amino group of an amino acid. For 26, the wavy line on the left is a bound between an amino acid having an alkyne group and the wavy line on the right is a bound between an amino acid having an azide group.

TABLE 3

#
Name
Structure

1
Nle(εN₃) x C₅

embedded image

2
Nle(εN₃x PEG₃

embedded image

3
Nle(εN₃) x PEG₄

embedded image

4
Nle(εN₃) x PEG₅

embedded image

5
Nle(εN₃) x PEG₆

embedded image

6
Nle(εN₃) x PEG₈

embedded image

7
Nle(εN₃) x PEG₁₀

embedded image

8
Nle(εN₃) x PEG₁₃

embedded image

9
Nle(εN₃) x PEG₁₄

embedded image

10
Nle(εN₃) x PEG₂₅

embedded image

11
Nle(εN₃) x (PEG₂)C₅

embedded image

12
Nle(εN₃) x (PEG₂)₃C₅

embedded image

13
Nle(εN₃) x (PEG₂₄)(PEG₄)

embedded image

14
Nle(εN₃) x (PEG₃₆)(PEG₄)

embedded image

15
Nle(εN₃) x PEG₁₂(LysγE-C₁₆) C₅

embedded image

16
Nle(εN₃) x BCN

embedded image

17
Lys(PEG₂)C₅N₃x C₅)

embedded image

18
Lys(PEG₂)(PEG₂)C₅N₃x C₅)

embedded image

19
Lys(PEG₂)₂γEC₁₆N₃x C₅)

embedded image

20
Nle(εN₃) x (PEG₃₆)₂(PEG₅)

embedded image

21
Nle(εN₃) x propargyl-C5- Lys(γE-C₁₆)—PEG₂₄

embedded image

22
Nle(εN₃) x propargyl-C5- Lys(γE-C₁₂)—PEG₁₂

embedded image

23
Nle(εN₃) x propargyl-C5- Lys(γE-C₁₆)—PEG₄

embedded image

24
Nle(εN₃) x propargyl-C5- Lys(γE-C₁₈—OH)—PEG₄

embedded image

25
C8 hydrocarbon linker

embedded image

26
pra x azide

embedded image

FIG. 5 shows an exemplary insulin-incretin conjugate in which the Nle amino acid of PEP74* is conjugated to the amino group of the Phe at position B1 of the B-chain peptide.

FIG. 9A, FIG. 9B, FIG. 9C, FIG. 9D, FIG. 9E, FIG. 9F, FIG. 9G, FIG. 9H, FIG. 9I, FIG. 9J, FIG. 9K, and FIG. 9L, which show exemplary insulin-incretin conjugates in which the Norleucine (Nle) amino acid of the incretin is conjugated to the amino group of the Phe at position B1 of the B-chain peptide.

FIG. 10A, FIG. 10B, FIG. 10C, FIG. 10D, FIG. 10E, FIG. 10F, and FIG. 10G, which show exemplary insulin-incretin conjugates in which the epsilon amino group of Lys of the incretin is conjugated to the amino group of the Phenylalanine (Phe) at position B1 of the B-chain peptide.

FIG. 11, which shows exemplary insulin-incretin conjugates CON106 and CON107.

Pharmaceutical Compositions

Further provided are pharmaceutical compositions comprising a therapeutically effective amount of one or more of the peptides disclosed herein for the treatment of a metabolic disorder in an individual. Such disorders include, but are not limited to, obesity, metabolic syndrome or syndrome X, type II diabetes, complications of diabetes such as retinopathy, hypertension, dyslipidemias, cardiovascular disease, gallstones, osteoarthritis, and certain forms of cancers. The obesity-related disorders herein are associated with, caused by, or result from obesity.

“Obesity” is a condition in which there is an excess of body fat. The operational definition of obesity is based on the Body Mass Index (BMI), calculated as body weight per height in meters squared (kg/m2). “Obesity” refers to a condition whereby an otherwise healthy subject has a Body Mass Index (BMI) greater than or equal to 30 kg/m2, or a condition whereby a subject with at least one co-morbidity has a BMI greater than or equal to 27 kg/m2. An “obese subject” is an otherwise healthy subject with a Body Mass Index (BMI) greater than or equal to 30 kg/m2 or a subject with at least one co-morbidity with a BMI greater than or equal to 27 kg/m2. A “subject at risk for obesity” is an otherwise healthy subject with a BMI of 25 kg/m2 to less than 30 kg/m2 or a subject with at least one co-morbidity with a BMI of 25 kg/m2 to less than 27 kg/m2.

The increased risks associated with obesity occur at a lower Body Mass Index (BMI) in Asians. In Asian countries, including Japan, “obesity” refers to a condition whereby a subject with at least one obesity-induced or obesity-related co-morbidity that requires weight reduction or that would be improved by weight reduction, has a BMI greater than or equal to 25 kg/m2. In Asian countries, including Japan, an “obese subject” refers to a subject with at least one obesity-induced or obesity-related co-morbidity that requires weight reduction or that would be improved by weight reduction, with a BMI greater than or equal to 25 kg/m2. In Asian countries, a “subject at risk of obesity” is a subject with a BMI of greater than 23 kg/m2 to less than 25 kg/m2.

As used herein, the term “obesity” is meant to encompass all of the above definitions of obesity.

Obesity-induced or obesity-related co-morbidities include, but are not limited to, diabetes, non-insulin dependent diabetes mellitus—type 2, impaired glucose tolerance, impaired fasting glucose, insulin resistance syndrome, dyslipidemia, hypertension, hyperuricacidemia, gout, coronary artery disease, myocardial infarction, angina pectoris, sleep apnea syndrome, Pickwickian syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), fatty liver; cerebral infarction, cerebral thrombosis, transient ischemic attack, orthopedic disorders, arthritis deformans, lumbodynia, emmeniopathy, and infertility. In particular, co-morbidities include: hypertension, hyperlipidemia, dyslipidemia, glucose intolerance, cardiovascular disease, sleep apnea, diabetes mellitus, and other obesity-related conditions.

“Treatment” (of obesity and obesity-related disorders) refers to the administration of the compounds of the present invention to reduce or maintain the body weight of an obese subject. One outcome of treatment may be reducing the body weight of an obese subject relative to that subject's body weight immediately before the administration of the compounds of the present invention. Another outcome of treatment may be preventing body weight regain of body weight previously lost as a result of diet, exercise, or pharmacotherapy. Another outcome of treatment may be decreasing the occurrence of and/or the severity of obesity-related diseases. The treatment may suitably result in a reduction in food or calorie intake by the subject, including a reduction in total food intake, or a reduction of intake of specific components of the diet such as carbohydrates or fats; and/or the inhibition of nutrient absorption; and/or the inhibition of the reduction of metabolic rate; and in weight reduction in patients in need thereof. The treatment may also result in an alteration of metabolic rate, such as an increase in metabolic rate, rather than or in addition to an inhibition of the reduction of metabolic rate; and/or in minimization of the metabolic resistance that normally results from weight loss.

“Prevention” (of obesity and obesity-related disorders) refers to the administration of the compounds of the present invention to reduce or maintain the body weight of a subject at risk of obesity. One outcome of prevention may be reducing the body weight of a subject at risk of obesity relative to that subject's body weight immediately before the administration of the compounds of the present invention. Another outcome of prevention may be preventing body weight regain of body weight previously lost as a result of diet, exercise, or pharmacotherapy. Another outcome of prevention may be preventing obesity from occurring if the treatment is administered prior to the onset of obesity in a subject at risk of obesity. Another outcome of prevention may be decreasing the occurrence and/or severity of obesity-related disorders if the treatment is administered prior to the onset of obesity in a subject at risk of obesity. Moreover, if treatment is commenced in already obese subjects, such treatment may prevent the occurrence, progression or severity of obesity-related disorders, such as, but not limited to, arteriosclerosis, Type II diabetes, polycystic ovarian disease, cardiovascular diseases, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, and cholelithiasis.

The obesity-related disorders herein are associated with, caused by, or result from obesity. Examples of obesity-related disorders include overeating and bulimia, hypertension, diabetes, elevated plasma insulin concentrations and insulin resistance, dyslipidemias, hyperlipidemia, endometrial, breast, prostate and colon cancer, osteoarthritis, obstructive sleep apnea, cholelithiasis, gallstones, heart disease, abnormal heart rhythms and arrythmias, myocardial infarction, congestive heart failure, coronary heart disease, sudden death, stroke, polycystic ovarian disease, craniopharyngioma, the Prader-Willi Syndrome, Frohlich's syndrome, GH-deficient subjects, normal variant short stature, Turner's syndrome, and other pathological conditions showing reduced metabolic activity or a decrease in resting energy expenditure as a percentage of total fat-free mass, e.g, children with acute lymphoblastic leukemia. Further examples of obesity-related disorders are metabolic syndrome, also known as syndrome X, insulin resistance syndrome, sexual and reproductive dysfunction, such as infertility, hypogonadism in males and hirsutism in females, gastrointestinal motility disorders, such as obesity-related gastro-esophageal reflux, respiratory disorders, such as obesity-hypoventilation syndrome (Pickwickian syndrome), cardiovascular disorders, inflammation, such as systemic inflammation of the vasculature, arteriosclerosis, hypercholesterolemia, hyperuricaemia, lower back pain, gallbladder disease, gout, and kidney cancer. The compounds of the present invention are also useful for reducing the risk of secondary outcomes of obesity, such as reducing the risk of left ventricular hypertrophy.

The term “diabetes,” as used herein, includes both insulin-dependent diabetes mellitus (IDDM, also known as type I diabetes) and non-insulin-dependent diabetes mellitus (NIDDM, also known as Type II diabetes). Type I diabetes, or insulin-dependent diabetes, is the result of an absolute deficiency of insulin, the hormone which regulates glucose utilization. Type II diabetes, or insulin-independent diabetes (i.e., non-insulin-dependent diabetes mellitus), often occurs in the face of normal, or even elevated levels of insulin and appears to be the result of the inability of tissues to respond appropriately to insulin. Most of the Type II diabetics are also obese. The compounds of the present invention are useful for treating both Type I and Type II diabetes. The compounds are especially effective for treating Type II diabetes. The compounds of the present invention are also useful for treating and/or preventing gestational diabetes mellitus.

U.S. Pat. No. 6,852,690, which is incorporated herein in its entirety, discloses methods for enhancing metabolism of nutrients comprising administering to a non-diabetic patient a formulation comprising a nutritively effective amount of one or more nutrients or any combination thereof and one or more insulinotropic peptides. The peptides disclosed herein are insulinotropic and can be administered to patients with a disturbed glucose metabolism such as insulin resistance but no overt diabetes, as well as patients who for any reason cannot receive nutrition through the alimentary canal. Such patients include surgery patients, comatose patients, patients in shock, patients with gastrointestinal disease, patients with digestive hormone disease, and the like. In particular, obese patients, atherosclerotic patients, vascular disease patients, patients with gestational diabetes, patients with liver disease such as liver cirrhosis, patients with acromegaly, patients with glucorticoid excess such as cortisol treatment or Cushings disease, patients with activated counterregulatory hormones such as would occur after trauma, accidents and surgery and the like, patients with hypertriglyceridemia and patients with chronic pancreatitis can be readily and suitably nourished according to the invention without subjecting the patient to hypo- or hyperglycemia. In particular, the administration to such a patient aims to provide a therapy to as rapidly as possible deliver the nutritional and caloric requirements to the patient while maintaining his plasma glucose below the so-called renal threshold of about 160 to 180 milligrams per deciliter of glucose in the blood. Although normal patients not having glucose levels just below the renal threshold can also be treated according to the invention as described above, patients with disturbed glucose metabolism such as hyperglycemic patients whose plasma glucose level is just above the renal threshold also find the therapy suitable for their condition. In particular, such patients who have a degree of hyperglycemia below the renal threshold at intermittent intervals can receive a combination treatment of nutrients plus insulinotropic peptides according to any of the following regimens. Normal patients not suffering from such hyperglycemia can also be treated using the peptides disclosed herein.

The peptides disclosed herein may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such compositions comprise a therapeutically-effective amount of one or more of the peptides disclosed herein and a pharmaceutically acceptable carrier. Such a composition may also be comprised of (in addition to the peptides disclosed herein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. Compositions comprising the peptides disclosed herein can be administered, if desired, in the form of salts provided the salts are pharmaceutically acceptable. Salts may be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry.

The term “individual” is meant to include humans and companion or domesticated animals such as dogs, cats, horses, and the like. Therefore, the compositions comprising a compound as disclosed herein are also useful for treating or preventing obesity and obesity-related disorders in cats and dogs. As such, the term “mammal” includes companion animals such as cats and dogs.

The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like. The term “pharmaceutically acceptable salt” further includes all acceptable salts such as acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methylbromide, bromide, methylnitrate, calcium edetate, methylsulfate, camsylate, mucate, carbonate, napsylate, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, phosphate/diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutamate, stearate, glycollylarsanilate, sulfate, hexylresorcinate, subacetate, hydrabamine, succinate, hydrobromide, tannate, hydrochloride, tartrate, hydroxynaphthoate, teoclate, iodide, tosylate, isothionate, triethiodide, lactate, panoate, valerate, and the like which can be used as a dosage form for modifying the solubility or hydrolysis characteristics or can be used in sustained release or pro-drug formulations. It will be understood that, as used herein, references to the OXM analogs disclosed herein are meant to also include the pharmaceutically acceptable salts.

The following examples are intended to promote a further understanding of the present invention.

Example 1

A general procedure for synthesizing the peptides shown in Table 1 may be performed as follows.

The peptides may be synthesized by solid phase synthesis using Fmoc/t-Bu chemistry on a peptide multisynthesizer Symphony (Protein Technologies Inc.) on a 150 μmol scale, using either a Rink-amide PEG-PS resin (Champion, Biosearch Technologies, loading 0.28 mmol/g) or a Rink-amide PS resin (ChemImpex loading 0.47 mmol/g).

All the amino acids are dissolved at a 0.3 M concentration in DMF. The amino acids are activated with equimolar amounts of HATU (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate) solution 0.3 M in DMF, and a 2-fold molar excess of DIEA (N,N-diisopropylethylamine), solution 2M in NMP. The acylation reactions are performed in general for 1 hour with a 5-fold excess of activated amino acid over the resin free amino groups with double 45 minutes acylation reactions performed from His¹to Thr⁷, from D¹⁵to U¹⁶and from F²²to V²³.

The side chain protecting groups may be: tert-butyl for Glu, Ser, D-Ser, Thr and Tyr; trityl for Asn, Gln and His; tert-butoxy-carbonyl for Lys, Trp; and, 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl for Arg; His may be introduced as Boc-His(Trt)-OH at the end of the sequence assembly. Amino acid 2 (L-methionine-sulphone) may be introduced by acylation of Fmoc-L-methionine-sulphone-COOH; Nle(εN₃) (ε-azidonorleucine) was introduced by acylation of Fmoc-ε-azidonorleucine-COOH.

The lysine that may be used for linker-lipid derivatization, may be incorporated with a Dde [1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl] protecting group or Alloc (allyloxycarbonyl) protecting group on the side chain amino group. For those sequences comprising an alpha methyl amino acid and the corresponding following residue, the incorporation may be performed by manual coupling with HOAt (Hydroxybenzoazatriazole) and DIC (N,N′-diisopropylcarbodiimide).

At the end of the assembly, the Dde protecting group of Lys(Dde) is removed by treatment with 2% hydrazine in DMF and the Alloc protecting group of Lys(Alloc) is removed by treatment with Pd(PPh₃)₄and PhSiH₃. The side chains of Lys are derivatized with different linkers and fatty acids by incorporation of Fmoc-Glu-OtBu (γ-glutamic acid), Fmoc-PEG₂[8-(9-Fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid], the lipid diacids (Octadecanedioic acid; Eicosanedioic acid) and Azido acids (C₅N₃=5-azido pentinoic acid; C₁₀N₃=10-azido-decanoic acid; C₁₆N₃=16-azido-hexadecanoic acid) using HOAt and DIC as activators.

At the end of the synthesis, the dry peptide-resins are individually treated with 25 mL of the cleavage mixture, 88% TFA, 5% phenol, 2% triisopropylsilane and 5% water for 1.5 hours at room temperature. Each resin is then filtered and then added to cold methyl-t-butyl ether in order to precipitate the peptide. After centrifugation, the peptide pellets are washed with fresh cold methyl-t-butyl ether to remove the organic scavengers. The process may be repeated twice. Final pellets are dried, resuspended in H₂O, 20% acetonitrile, and lyophilized.

The crude peptides (140 mg in 3 mL of DMSO) are purified by reverse-phase HPLC using preparative Waters Deltapak C4 (40×200 mm, 15 μm, 300 Å) and using as eluents (A) 0.1% TFA in water and (B) 0.1% TFA in acetonitrile.

Analytical HPLC may be performed on an Acquity UPLC Waters Chromatograph with a BEH300 C4 Acquity Waters column 2.1×100 mm, 1.7 μm, at 45° C., using H₂O, 0.1% TFA (A) and CH₃CN, 0.1% TFA (B) as solvents. The peptides may be characterized by electrospray mass spectrometry on an Acquity SQ Detector.

Example 2

Synthesis of Linker 16-Azido esadecanoic acid may be performed as follows.

embedded image

To a solution of 16-bromo hexadecanoic acid in DMF, sodium azide (2 eq) is added. After 12 hours at 85 C°, the reaction mixture is cooled to room temperature. DCM is added and the organic phase is washed with HCl 0.1N, brine and dried over Na₂SO₄. The solvents are removed under reduced pressure and 16-azido hexadecanoic acid is obtained. ¹H NMR (400 MHz, CDCl₃-d₆, 300K) δ 12.35 (s, 1H), 3.30-3.22 (m, 2H), 2.40-2.32 (m, 2H), 1.69-1.56 (m, 4H), 1.4-1.2 (m, 20H).

Example 3

Synthesis of Linker Propargyl-PEG₂₅-acid may be as follows.

embedded image

Step 1: To a suspension of sodium hydride, 60% dispersion in mineral oil (18 mg, 0.450 mmol) in THF (1 mL) cooled in an ice bath is added a solution of hydroxy-PEG₂₄-t-butyl ester (250 mg, 0.208 mmol) in Tetrahydrofuran (THF) (1.5 mL). The reaction mixture is stirred for 15 minutes and propargyl bromide, 80% in toluene (26.9 μl, 0.249 mmol) is added. The ice bath is removed and the reaction is allowed to warm to room temperature (RT) and stirred overnight. The reaction is quenched with water (50 μL), diluted with EtOAc, dried over sodium sulfate, filtered and concentrated to give the crude product propargyl-PEG25-t-butyl ester.

Step 2: TFA (1 mL, 12.98 mmol) is added to the crude propargyl-PEG₂₅-t-butyl ester and the reaction is stirred at RT for one hour. The volatiles are evaporated and the residue is purified by mass-directed RP-HPLC (ACN/water with 0.1% ammonium hydroxide as modifier) to give propargyl-PEG₂₅-acid. MS: 1186 (M+1).

Example 4

Synthesis of Linker 2-(2-(2-(Pent-4-ynamido)ethoxy)ethoxy)acetic acid (Propargyl-C₅-PEG₂-acid) may be as follows.

embedded image

To a solution of 2-(2-(2-aminoethoxy)ethoxy)acetic acid (1.0 g, 6.13 mmol) and 2,5-dioxopyrrolidin-1-yl pent-4-ynoate (1.2 g, 6.13 mmol) in dimethylformamide (DMF) (10 mL) is added N,N-diisopropylethylamine (DIPEA) (1.28 ml, 7.35 mmol) at RT. The mixture is stirred at RT overnight. The reaction is quenched with water and lyophilized to dryness. The residue is purified by mass-directed RP-HPLC (ACN/water with 0.1% TFA as modifier) to give 2-(2-(2-(pent-4-ynamido)ethoxy)ethoxy)acetic acid. MS: 266 (M+23).

Example 5

Synthesis of Linker 10,19,28-Trioxo-3,6,12,15,21,24-hexaoxa-9,18,27-triazadotriacont-31-ynoic acid (Propargyl-C₅-(PEG₂)₃-acid).

embedded image

Step 1: In a 20 mL vial is added 2-(2-(2-(pent-4-ynamido)ethoxy)ethoxy)acetic acid (500 mg, 2.055 mmol) and DMSO (2 mL). TSTU (dimethylamino-(2,5-dioxopyrrolidin-1-yl)oxymethylidene]-dimethylazanium; tetrafluoroborate; 681 mg, 2.261 mmol) and triethylamine (573 μl, 4.11 mmol) are added. The mixture is stirred at RT for two hours. The freshly prepared N-Hydroxysuccinimide (NHS) ester is then added to a solution of 2-(2-aminoethoxy)ethoxy)acetic acid (419 mg, 2.57 mmol) and triethylamine (2.86 ml, 20.55 mmol) in DMSO (1 mL). The reaction is stirred at RT for 48 hours and triethylamine is removed under reduced pressure. Two drops of trifluoroacetate (TFA) are added to neutralize the reaction. The mixture is filtered through a syringe filter. The residue is purified by mass-directed RP-HPLC (ACN/water with 0.1% TFA as modifier) to give 10,19-dioxo-3,6,12,15-tetraoxa-9,18-diazatricos-22-ynoic acid.

Step 2: In a 20 ml vial is added 10,19-dioxo-3,6,12,15-tetraoxa-9,18-diazatricos-22-ynoic acid (132 mg, 0.340 mmol) and DMSO (1 mL). TSTU (113 mg, 0.374 mmol) and triethylamine (95 μl, 0.680 mmol) are added. The mixture is stirred at RT for two hours. The freshly prepared NHS ester is then added to a solution of 2-(2-(2-aminoethoxy)ethoxy)acetic acid (111 mg, 0.680 mmol) and triethylamine (474 μl, 3.40 mmol) in DMSO (1 mL). The reaction is quenched with TFA aqueous solution to slightly acidic. Water is added and the mixture is lyophilized to dryness. The residue purified by mass-directed RP-HPLC (ACN/water with 0.1% TFA as modifier) to give 10,19,28-trioxo-3,6,12,15,21,24-hexaoxa-9,18,27-triazadotriacont-31-ynoic acid. MS: 534 (M+1).

Example 6

Synthesis of Linker Propargyl-C₅-Lys(γE-^tBuC₁₆)-PEG₁₂-acid.

embedded image

Step 1: To a mixture of L-Glu-O^tBu (580 mg, 2.85 mmol) and NaHCO₃(527 mg, 6.28 mmol) in water (10 mL) and THF (5 ml) at RT is added a solution of 2,5-dioxopyrrolidin-1-yl palmitate (1.01 g, 2.85 mmol) in THF (10 ml). The reaction mixture is stirred at RT overnight. THF is evaporated under reduced pressure. The reaction mixture is neutralized with TN HCl (7 mL), diluted with water, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated to give the crude product (S)-5-(tert-butoxy)-5-oxo-4-palmitamidopentanoic acid.

Step 2: To a mixture of H-Lys(Boc)-OH (600 mg, 2.436 mmol) and NaHCO₃(450 mg, 5.36 mmol) in water (10 mL) and THF (5 mL) at RT is added a solution of 2,5-dioxopyrrolidin-1-yl pent-4-ynoate (475 mg, 2.436 mmol) in THF (10 mL). The reaction mixture is stirred at RT overnight. THF is evaporated under reduced pressure. The reaction mixture is neutralized with TN HCl (7 mL), diluted with water, extracted with EtOAc, washed with brine, dried over sodium sulfate, filtered and concentrated to give the product (S)-6-((tert-butoxycarbonyl)amino)-2-(pent-4-ynamido)hexanoic acid as light yellow oil. TFA (3 mL, 38.9 mmol) is added to the crude (S)-6-((tert-butoxycarbonyl)amino)-2-(pent-4-ynamido)hexanoic acid (0.795 g, 2.436 mmol) at room temperature and the reaction mixture is stirred for one hour. TFA is evaporated under reduced pressure and the residue is quenched with water and lyophilized to give the product (S)-6-amino-2-(pent-4-ynamido)hexanoic acid, 2TFA.

Step 3: In a 20 mL vial is added (S)-5-(tert-butoxy)-5-oxo-4-palmitamidopentanoic acid (500 mg, 1.13 mmol) and DMSO (1 mL). TSTU (375 mg, 1.245 mmol) and triethylamine (316 μl, 2.264 mmol) are added. The mixture is stirred at RT for two hours. The freshly prepared NHS ester is then added to a solution of (S)-6-amino-2-(pent-4-ynamido)hexanoic acid, 2TFA (643 mg, 1.415 mmol) and triethylamine (1.58 mL, 11.32 mmol) in DMSO (1 mL). The reaction mixture is stirred at RT overnight. The reaction is diluted with water, acidified with 1N HCl, extracted with EtOAc, washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue is purified by mass-directed RP-HPLC (ACN/water with 0.1% TFA as modifier) to give N⁶—((S)-5-(tert-butoxy)-5-oxo-4-palmitamidopentanoyl)-N²-(pent-4-ynoyl)-L-lysine.

Step 4: In a 20 mL vial is added N⁶—((S)-5-(tert-butoxy)-5-oxo-4-palmitamidopentanoyl)-N²-(pent-4-ynoyl)-L-lysine (100 mg, 0.154 mmol) and DMSO (0.8 mL). TSTU (51 mg, 0.169 mmol) and triethylamine (43 μl, 0.308 mmol) is added. The mixture is stirred at RT for two hours. The freshly prepared NHS ester is then added to a solution of amino-PEG₁₂-acid (124 mg, 0.192 mmol) and triethylamine (214 μl, 1.539 mmol) in DMSO (0.5 mL). The reaction is stirred at RT overnight. The reaction is diluted with water and lyophilized to dryness. The residue is purified by mass-directed RP-HPLC (ACN/water with 0.1% TFA as modifier) to give propargyl-C₅-Lys(γE-^tBu₁₆)-PEG₁₂-acid. MS: 1250 (M+1).

Example 7

Synthesis of Propargyl-(PEG₄)(PEG₂₄)-acid.

embedded image

Amino-PEG₂₄-acid (100 mg, 0.087 mmol) and NaHCO₃(16.12 mg, 0.192 mmol) are suspended in water (2 mL) and THF (1 ml) at room temperature. To the mixture is added a solution of propargyl-PEG₄-NHS (32.7 mg, 0.092 mmol) in THF (2 mL). The reaction is stirred at RT overnight. The reaction is neutralized by 0.1 M HCl (2 mL) and lyophilized to dryness. The residue is purified by mass-directed RP-HPLC (ACN/water with 0.1% TFA as modifier) to give propargyl-(PEG₄)(PEG₂₄)-acid. MS: 695 (M+2)/2.

Example 8

Synthesis of Propargyl-(PEG₄)(PEG₃₆)-acid.

embedded image

Amino-PEG₃₆-acid (100 mg, 0.060 mmol) and NaHCO₃(11.03 mg, 0.131 mmol) are suspended in water (2 mL) and THF (1 mL) at room temperature. To the mixture is added a solution of propargyl-PEG₄-NHS (22.4 mg, 0.063 mmol) in THF (2 mL). The reaction is stirred at RT overnight. The reaction is neutralized by 0.1 M HCl (2 mL) and lyophilized to dryness. The residue is purified by mass-directed RP-HPLC (ACN/water with 0.1% TFA as modifier) to give propargyl-(PEG₄)(PEG₃₆)-acid. MS: 640 (M+3)/3.

Example 9

Synthesis of Propargyl-(PEG₅(PEG₃₆)₂-acid.

embedded image

Step 1: Amino-PEG₃₆-acid (1.04 g, 0.623 mmol) and NaHCO₃(115 mg, 1.37 mmol) are suspended in water (20 mL) and THF (10 mL) at room temperature. To the mixture is added a solution of propargyl-PEG₅-NHS (262 mg, 0.65 mmol) in THF (20 mL). The reaction is stirred at RT overnight. The reaction is neutralized by 0.1 M HCl (20 mL) and lyophilized to dryness. The residue is purified by mass-directed RP-HPLC (ACN/water with 0.1% TFA as modifier) to give propargyl-(PEG₅)(PEG₃₆)-acid as white solids.

Step 2: In a 20 ml vial was added propargyl-(PEG₅)(PEG₃₆)-acid (100 mg, 0.051 mmol) and DMSO (0.8 mL). TSTU (16.88 mg, 0.056 mmol) and triethylamine (14.21 μL, 0.102 mmol) was added. The mixture was stirred at RT for two hours. The freshly prepared NHS ester is then added to a solution of amino-PEG₃₆-acid (107 mg, 0.064 mmol) and triethylamine (71.1 μL, 0.510 mmol) in DMSO (0.5 mL). The reaction is stirred at RT overnight. The reaction is diluted with water and lyophilized to dryness. The residue is purified by mass-directed RP-HPLC (ACN/water with 0.1% TFA as modifier) to give proparyl-(PEG₅)(PEG₃₆)₂-acid as white solids. MS: 517.85 (M+7)/7.

Example 10

Synthesis of N^αA1N^ε29bis-Boc RHI.

embedded image

RHI (10 g) is dissolved in DMSO (200 mL) at RT the mixture is stirred at RT until homogeneous. To the solution is added 2,2,6,6-tetramethylpiperidine (5.8 mL) followed slow addition of a solution of tert-butyl (2,5-dioxopyrrolidin-1-yl) carbonate (Boc-OSu, 0.8 g) in DMSO (10 mL). The reaction is agitated for four hours and the mixture is transferred to IPAc (1 L) over 20 minutes. The slurry is centrifuged for two hours and the solid is filtered, washed with IPAc (20 ml×3) and dried under vacuum to give N^αA1N^εB29bis-Boc RHI.

Example 11

Synthesis of N^αA1-propargyl-C₅RHI (INS1).

embedded image

Insulin (655 mg, 0.113 mmol) is first dissolved in pH 2.5 water (12 mL) and then adjusted to pH 8.5 with 1N NaOH. A stock solution of 2,5-dioxopyrrolidin-1-yl pent-4-ynoate (35 mg, 0.174 mmol) in DMSO (200 μL) is added in four portions to the above insulin solution over one hour. The pH is maintained at 8.0-8.5. The reaction is quenched with ethanolamine (17 μL) after five hours and adjusted to pH 7.0. The reaction mixture is first purified by IEC HPLC with the following conditions: PolySULFOETHYL ATM column, 250×21.0 mm, 5 um, 1000 A, eluent (A: 1 L ACN, 3 L H₂O, 4 ml H₃PO₄; B: 1 L ACN, 2.6 L H₂O, 400 ml 5M NaCl, 4 ml H₃PO₄), FR=15 mL/minute, wavelength 210 nm, B % from 10% to 40%. The major fractions are concentrated down to 15 mL by 8×10K Amicon centrifuge tube. The concentrated crude is further purified by RP-HPLC, using the separation condition (28-33%) 0.05% TFA in ACN/H₂O on Kromasil 100-10-C8 from AkzoNobel, 100 A and 10 uM 50×250 mm column; FR=85 ml/min, ramp 25 minutes, wavelength=210 nm. The desired fractions are collected and lyophilized to N^αA1-propargyl-C₅RHI.

Example 12

Synthesis of N^αB1-propargyl-C5 RHI (INS2).

embedded image

Step 1: RHI (2.74 g, 0.472 mmol) is dissolved in DMSO (50 mL) and the mixture is stirred at RT until homogeneous (about 45 minutes). To the solution is added 1,1,3,3-tetramethylguanidine (0.19 mL, 1.179 mmol) and followed by slow addition of a solution of Boc-OSu (0.216 g, 1.005 mmol) DMSO (2.1 mL, plus 0.4 mL wash) over 30 minutes. The reaction is further stirred for 1.5 hours for N^αA1N^εB29bis-Boc RHI to be formed. To the reaction mixture is added a solution of 2,5-dioxopyrrolidin-1-yl pent-4-ynoate in DMSO (1 mL) using a syringe pump over 30 minutes. After stirring for two hours, the reaction mixture is dropwise added to a stirred 275 mL of IPAc to precipitate the product. The white solids are filtered, washed with IPAc and dried under N₂and vacuum for one hour.

Step 2: TFA (15 mL, 195 mmol) is added to the above crude material (3 g, 0.493 mmol) and the reaction is stirred and sonicated until solids fully dissolved (about 30 minutes). The reaction mixture is dropwise added to water (75 mL) and the precipitated solids are filtered and dried under N₂and vacuum. The crude material is purified using RP-HPLC to give the N^αB1-propargyl-C₅RHI.

Example 13

Synthesis of N^αB1-propargyl-PEG₄RHI (INS3).

embedded image

Step 1: To a solution of N^αA1N^εB29bis-Boc RHI (317 mg, 0.053 mmol) in DMSO (2 mLl) is added Et₃N (37 μL, 0.264 mmol) and followed by slow addition of alkyne-PEG₄-NHS (2,5-dioxopyrrolidin-1-yl 4,7,10,13-tetraoxahexadec-15-ynoate, 37.7 mg, 0.106 mmol) in DMSO (800 μL) via syringe pump over one hour. The reaction mixture is stirred at RT overnight. The reaction mixture is dropwise added to stirred isopropyl acetate (IPAc, 50 mL) to precipitate the product. The white precipitate is collected by filtration and dried under nitrogen gas and vacuum for one hour to give the crude product N^αA1N^εB29bis-Boc, N^αB1-propargyl-PEG₄RHI.

Step 2: TFA (1.5 mL, 19.47 mmol) is added to the crude N^αA1N^εB29bis-Boc, N^αB1-PEG₄-alkyne RHI. The reaction is stirred and sonicated at RT until solids fully dissolved (about 30 minutes). The reaction mixture is dropwise added to tert-butyl methyl ether (TBME, 20 mL) and solids precipitated out. The reaction is filtered, washed with TBME and IPAc. The white solid is dried under nitrogen gas and vacuum for one hour to give crude product as white solids. The solids are dissolved in water (15 mL). It is purified by RP-HPLC column using the separation condition (28-35%) 0.05% TFA in AcCN/H₂O on Kromasil 100-10-C8 from AkzoNobel, 100 A and 10 uM 50×250 mm column; FR=85 mL/minute, ramp 25 minutes, wavelength=210 nm. The fractions are collected and lyophilized to give N^αB1-propargyl-PEG₄-RHI.

INS4-INS6 shown below may be prepared using the methodology herein and the general procedure described for INS3.

INS4
N^αB1-propargyl-PEG₃RHI embedded image

INS5
N^αB1-propargyl-PEG₅RHI embedded image

INS6
N^αB1-BCN—PEG₄(endo) RHI embedded image

BCN = bicyclononyne

Example 14

Synthesis of N^αB1-propargyl-PEG₆RHI (INS7).

embedded image

In a small vial, propargyl-PEG₆-acid (4,7,10,13,16,19-hexaoxadocos-21-yn-1-oic acid, 11.6 mg, 0.033 mmol) is dissolved in DMSO (500 μL). To the solution is added TSTU (O—(N-Succinimidyl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate, 10.0 mg, 0.033 mmol) and Et₃N (4.6 μl, 0.033 mmol). The mixture is stirred at RT for two hours to give the crude propargyl-PEG₆-NHS. The freshly made propargyl-PEG₆-NHS solution is added to a solution of N^αA1N^εB29bis-Boc RHI (100 mg, 0.017 mmol) and Et₃N (12 μL, 0.086 mmol) in DMSO (1 mL) via syringe pump over 30 minutes. The reaction mixture is stirred at RT for two hours. The reaction mixture is dropwise added to a stirred IPAc (20 mL) to precipitate the product. The white precipitate is collected by filtration and dried under nitrogen gas and vacuum for one hour to give the crude product N^αA1N^εB29bis-Boc, N^αB1-propargyl-PEG₆RHI.

TFA (0.5 ml, 6.49 mmol) is added to the crude N^αA1N^εB29bis-Boc, N^αB1-PEG₆-alkyne RHI. The reaction is stirred and sonicated at RT until solids fully dissolved (about 30 minutes). The reaction mixture is dropwise added to tert-butyl methyl ether (TBME, 10 mL) and solids precipitated out. The reaction is filtered, washed with TBME and IPAc. The white solid is dried under nitrogen gas and vacuum for one hour to give crude product as white solids. The solids are dissolved in water (8 mL). It is purified by RP-HPLC column using the separation condition (28-35%) 0.05% TFA in AcCN/H₂O on Kromasil 100-10-C8 from AkzoNobel, 100 A and 10 μM 50×250 mm column; FR=85 mL/minute, ramp 25 minutes, wavelength=210 nm. The fractions are collected and lyophilized to give the N^αB1-propargyl PEG₆RHI.

INS 8-INS15 shown below may be prepared using the methodology herein and the general procedure described for INS7.

INS8
N^αB1-propargyl-PEG₈RHI embedded image

INS9
N^αB1-propargyl-PEG₁₀RHI embedded image

INS10
N^αB1-propargyl-PEG₁₃RHI embedded image

INS11
N^αB1-propargyl-PEG₁₄RHI embedded image

INS12
N^αB1-propargyl-PEG₂₅RHI embedded image

INS13
N^αB1-propargyl-PEG₂—C₅RHI embedded image

INS14
N^αB1-propargyl-C5—(PEG₂)₃RHI embedded image

INS15
N^αB1-propargyl-C5-Lys(γE-C₁₆)—PEG₁₂— RHI embedded image

Example 15

Synthesis of N^εB29-propargyl-C₅RHI (INS16).

embedded image

General Method: In an appropriate sized container, RHI is dissolved, with gentle stirring, at room temperature in a mixed solvent: 2:3 v/v 0.1 M Na₂CO₃:AcCN. After the mixture cleared, the pH is adjusted to the value of 10.5-10.8 using alkaline solution, e.g., 0.1 N NaOH. In a separate vial, 2,5-dioxopyrrolidin-1-yl pent-4-ynoate is dissolved in an organic solvent, e.g., DMSO, at room temperature. Aliquots of the solution of the activated ester is added over a period of time to the solution containing insulin until UPLC chromatogram showed that most of the unmodified insulin had been reacted and that a substantial portion of the reaction mixture had been converted into B29-conjugated insulin. The reaction is quenched by the addition of an amine nucleophile, e.g., 2-aminoethanol. The reaction solution is stirred at room temperature for 30 minutes. The resulting solution is carefully diluted with cold H₂O (20×) at 0° C. and its pH is adjusted to a final pH of 2.5 using 1 N HCl (and 0.1 N NaOH if needed). The solution is first concentrated by ultrafiltration, either through a tangential flow filtration (TFF) system or using Amicon Ultra-15 Centrifugal Units, with 1K, 3K or 10K MWCO membrane. The concentrated solution may be first subjected to ion exchange chromatography (PolySULFOETHYL A column, PolyLC Inc., 250×21 mm, 5 m, 1000 Å; Buffer A: 0.1% (v/v)H₃PO₄/25% AcCN; Buffer B: 0.1% (v/v)H₃PO₄/25% AcCN/0.5 M NaCl). Fractions containing B29-conjugate with desired purity are combined and concentrated using TFF system or Amicon Ultra-15. The resulting solution is then further purified by reverse phase HPLC (Waters C4 250×50 mm column, 10 m, 1000 Å column or Kromasil C8 250×50 mm, 10 m, 100 Å column; Buffer A: 0.05-0.1% TFA in water; Buffer B: 0.05-0.1% TFA in AcCN). Fractions containing the title conjugate are combined and freeze-dried or buffer exchanged using TFF system and/or Amicon Ultra-15 to give the N^εB29-propargyl-C₅RHI. MS: 1472.56 (M+4)/4.

Example 16

Synthesis of N^εB29-propargyl-PEG₄RHI (INS17).

embedded image

In a 20 mL vial, RHI (200 mg, 0.034 mmol) is dissolved in DMSO (1 mL) and aged at RT until homogeneous. 1,1,3,3-tetramethylguanidine (86 μl, 0.689 mmol) is added and followed by slow addition of alkyne-PEG₄-NHS (2,5-dioxopyrrolidin-1-yl 4,7,10,13-tetraoxahexadec-15-ynoate, 13.5 mg, 0.038 mmol) solution in DMSO (0.5 ml) via syringe pump over 30 min. The reaction is stirred at RT for one hour. The mixture is added dropwise to a mixed solvent IPAc/TBME(20 mL, 4:1) to precipitate out the product. HOAc (200 μl, 3.49 mmol) is added. The solids are filtered and dried under nitrogen gas and vacuum for 30 minutes. The solids are dissolved in 15 mL mix solvent (80% water, 20% ACN, pH=3.0), adjusted pH to 3. The residue is purified by RP-HPLC column, using the separation condition (28-35%) 0.05% TFA in AcCN/H₂O on Kromasil 100-10-C8 from AkzoNobel, 100 A and 10 μM 50×250 mm column; FR=85 mL/minute, ramp 25 minutes, wavelength=210 nm. The fractions are collected and lyophilized to give N^εB29-propargyl-PEG₄RHI.

Example 17

N^εB29-propargyl-PEG₄insulin glargine (INS18).

embedded image

N^εB29-propargyl-PEG₄insulin glargine may be prepared using the methodology herein and the general procedure described for INS16.

Example 18

Synthesis of N^εB29-propargyl-PEG₁₃RHI (INS19).

embedded image

In a small vial, propargyl-PEG₁₃-acid (4,7,10,13,16,19,22,25,28,31,34,37,40-tridecaoxatritetracont-42-ynoic acid, 24.9 mg, 0.038 mmol) is dissolved in DMSO (500 μL). To the solution is added TSTU (11.4 mg, 0.038 mmol) and Et₃N (7.2 μl, 0.052 mmol). The mixture is stirred at RT for two hours. The freshly made propargyl-PEG6-NHS solution is added to a solution of RHI (200 mg, 0.034 mmol) and 1,1,3,3-tetramethylguanidine (0.086 ml, 0.689 mmol) in DMSO two mL via syringe pump over 60 minutes. The reaction mixture is stirred at RT for 30 minutes. The reaction is quenched with 2-aminoethanol (10.4 μl, 0.172 mmol) for 10 minutes. The reaction mixture is dropwise added to a stirred 20 mL of IPAc/TBME (4:1) to precipitate the product. The solids are filtered, washed with IPAc, and dried under nitrogen gas and vacuum for one hour. The residue is purified by RP-HPLC (ACN/water with 0.1% TFA as modifier) to give N^εB29-propargyl-PEG₁₃RHI.

INS20-INS21 shown below may be prepared using the methodology herein and the general procedure described for INS19.

INS20
N^εB29-propargyl-(PEG₄)—(PEG₂₄) RHI embedded image

INS21
N^εB29-propargyl-(PEG₄)—(PEG₃₆) RHI embedded image

INS25
N^εB29-propargyl-(PEG₅)—(PEG₃₆)₂RHI embedded image

Example 19

Synthesis of N^αB1-propargyl-C5 N^εB29C₁₄RHI (INS22).

embedded image

Step 1: N^εB29C₁₄RHI (2.74 g, 0.472 mmol) is dissolved in DMSO (50 mL) and the mixture is stirred at RT until homogeneous (about 45 minutes). To the solution is added 1,1,3,3-tetramethylguanidine (0.19 mL, 1.179 mmol) and followed by slow addition of a solution of Boc-OSu (0.216 g, 1.005 mmol) DMSO (2.1 mL, plus 0.4 mL wash) over 30 minutes. The reaction is further stirred for 1.5 hours for N^αA1Boc RHI to be formed. To the reaction mixture is added a solution of 2,5-dioxopyrrolidin-1-yl pent-4-ynoate in DMSO (1 mL) using a syringe pump over 30 minutes. After stirring for two hours, the reaction mixture is dropwise added to a stirred 275 mL of IPAc to precipitate the product. The white solids are filtered, washed with IPAc and dried under N₂and vacuum for one hour.

Example 20

Synthesis of N^αB1-propargyl-C₅N^εB29γE-C₁₆RHI (INS23).

embedded image

Step 1: N^εB29γE-C₁₆RHI (2.74 g, 0.472 mmol) is dissolved in DMSO (50 mL) and the mixture is stirred at RT until homogeneous (about 45 minutes). To the solution is added 1,1,3,3-tetramethylguanidine (0.19 mL, 1.179 mmol) and followed by slow addition of a solution of Boc-OSu (0.216 g, 1.005 mmol) DMSO (2.1 mL, plus 0.4 mL wash) over 30 minutes. The reaction is further stirred for 1.5 hours for N^αA1Boc RHI to be formed. To the reaction mixture is added a solution of 2,5-dioxopyrrolidin-1-yl pent-4-ynoate in DMSO (1 mL) using a syringe pump over 30 minutes. After stirring for two hours, the reaction mixture is dropwise added to a stirred 275 mL of IPAc to precipitate the product. The white solids are filtered, washed with IPAc and dried under N₂and vacuum for one hour.

Example 21

Synthesis of N^αB1-propargyl-PEG₁₃N^εB29γE-C₁₆RHI (INS24).

embedded image

Example 21

General procedure A for insulin-incretin conjugate preparation (with TBTA ligand) using copper(I) catalyzed Azide-Alkyne Cycloaddition (CuAAC) (schematically shown in FIG. 1B):

A 10 mM Cu(II)-TBTA in 55% DMSO stock solution is prepared as follows: CuSO₄.5H₂O (50 mg) is dissolved in water (10 mL) and Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 116 mg) is dissolved in DMSO (11 mL). The two solutions are then mixed slowly at 0° C.

In a 20 mL vial, incretin peptide comprising an azido group (11 mg, 2.79 μmol) is dissolved in a pre-mixed solvent DMSO/H₂O (5 mL, 2:3). In another 50 mL centrifuge tube insulin intermediate comprising an alkyne group, e.g. N^αB1-propargyl-PEG₄RHI, (17.4 mg, 2.87 μmol) is dissolved in a pre-mixed solvent DMSO/H₂O (5 ml, 2:3), and then 2 M triethylammonium acetate buffer solution (pH 7.0, 1.2 mL) is added. The above two solutions are mixed on a vortex and degassed by gently bubbling nitrogen gas. To the reaction mixture is added freshly prepared 5 mM ascorbic acid solution (1.2 ml) and the mixture vortexed. The solution is degassed by bubbling N₂for one minute. A stock solution of 10 mM Cu(II)-TBTA in 55% DMSO (0.6 mL) is added and the mixture is flushed with N₂for two minutes. The mixture is shaken slowly overnight. The reaction mixture is diluted with 50 mL mixed solvent (80% water, 20% ACN pH=3.0) and the pH is adjusted to 3.0. The solution is concentrated using 3K Amicon centrifuge tube to final total volume 15 mL. The residue is purified by RP-HPLC, using the separation condition (31-46%) 0.05% TFA in ACN/H₂O on Kromasil 100-10-C8 from AkzoNobel, 100 A and 10 μM 50×250 mm column; FR=85 mL/minute, ramp 25 minutes, wavelength=210 nm. The desired fractions are collected and lyophilized to give the insulin-incretin conjugate wherein the azido and alkynyl groups have formed a 1,4-disubstituted 1,2,3-triazole. MS: 1993 (M+5)/5.

Example 22

General procedure B for CuAAC conjugate preparation (without TBTA ligand): insulin intermediate comprising an alkyne group, e.g. 1N^εB29-propargyl-(PEG₄)-(PEG₂₄) RHI, (33 mg, 4.60 μmol) and incretin peptide comprising an azido group (23.9 mg, 5.52 μmol) are dissolved in DMSO (3.3 mL). Under nitrogen flow, to the above solution in a water bath is added dropwise a stock solution of CuSO₄5H₂O in water (1.23 mL, 0.014 mmol, 2.8 mg/ml). Subsequently, a freshly prepared solution of sodium ascorbate in water (0.969 mL, 0.018 mmol, 3.76 mg/mL) is added dropwise. The reaction is stirred at RT for two hours, quenched with a mixed solvent (10 mL, 80% water, 20% ACN, pH=3.0) and pH is adjusted to 3.0. The reaction solution is purified by RP-HPLC column, using the separation condition (32-47%) 0.05% TFA in ACN/H₂O on Kromasil 100-10-C8 from AkzoNobel, 100 A and 10 μM 50×250 mm column; FR=85 mL/minute, ramp 25 minutes, wavelength=210 nm. The desired fractions are collected and lyophilized to give the insulin-incretin conjugate wherein the azido and alkynyl groups have formed a 1,4-disubstituted 1,2,3-triazole. MS: 1849 (M+6)/6.

Example 23

Preparation of N^αB1-BCN-PEG₄(endo) RHI-incretin peptide conjugate using Copper-free click chemistry.

Insulin intermediate, e.g., N^αB1-BCN-PEG₄(endo), (17 mg, 2.73 μmol) is dissolved in water (3 mL) to give a clear solution. To the solution is added 0.5 mL pH 7 buffer (2 M triethylammonium acetate buffer, pH=7.0:2.78 mL Et₃N mixed with 1.14 ml acetic acid, water is added to 10 mL, and the pH is adjusted to 7.0). Incretin peptide comprising an azido group (14.8 mg, 3.41 μmol) is dissolved in a mixed solvent (3 mL, water/ACN 3:2). The two solutions are mixed together and stirred at RT for six hours. The solution is adjusted pH with 1.0 N HCl until the solution turns clear (total volume 8 mL). The reaction solution is purified by RP-HPLC column, using the separation condition (31-47%) 0.05% TFA in AcCN/H₂O on Kromasil 100-10-C8 from AkzoNobel, 100 A and 10 uM 50×250 mm column; FR=85 mL/minute, ramp 25 minutes, wavelength=210 nm. Fractions are collected and lyophilized to give the product. MS: 1691 (M+6)/6.

Example 24

Table 4 shows various insulin-incretin conjugates (“CON”) that have been synthesized according to methods disclosed herein. Each conjugate was synthesized from a particular peptide having a linker with a terminal azido group and a particular insulin having a linker with a terminal alkynal group to produce the conjugate in which the insulin and peptide are linked via the azido and alkynal groups in a 1,4 disubstituted 1,2,3-triazol linkage, except for CON23 which is linked via a 1,4,5 disubstituted 1,2,3-triazol.

TABLE 4

Conjugate

Components

Name
Peptide
Insulin

CON1
PEP68
INS16

CON2
PEP68
INS2

CON3
PEP68
INS1

CON4
PEP69
INS2

CON5
PEP69
INS16

CON6
PEP69
INS1

CON7
PEP70
INS16

CON8
PEP70
INS1

CON9
PEP70
INS2

CON10
PEP71
INS16

CON11
PEP71
INS2

CON12
PEP71
INS1

CON13
PEP72
INS2

CON14
PEP73
INS2

CON15
PEP73
INS16

CON16
PEP74
INS2

CON17
PEP74
INS16

CON19
PEP69
INS3

CON20
PEP69
INS10

CON21
PEP74
INS3

CON22
PEP74
INS10

CON23
PEP74
INS6

CON24
PEP74
INS4

CON25
PEP74
INS5

CON26
PEP74
INS13

CON27
PEP74
INS7

CON28
PEP1
INS2

CON29
PEP2
INS2

CON30
PEP3
INS2

CON31
PEP4
INS2

CON32
PEP5
INS2

CON33
PEP6
INS2

CON34
PEP7
INS2

CON35
PEP8
INS2

CON36
PEP9
INS2

CON37
PEP10
INS2

CON38
PEP11
INS2

CON39
PEP12
INS2

CON40
PEP13
INS2

CON41
PEP14
INS2

CON42
PEP15
INS2

CON43
PEP16
INS2

CON44
PEP17
INS2

CON45
PEP18
INS2

CON46
PEP19
INS2

CON47
PEP20
INS2

CON48
PEP21
INS2

CON49
PEP22
INS2

CON50
PEP25
INS2

CON51
PEP26
INS2

CON52
PEP27
INS2

CON53
PEP28
INS2

CON55
PEP74
INS8

CON56
PEP74
INS9

CON57
PEP74
INS11

CON58
PEP69
INS22

CON59
PEP69
INS23

CON60
PEP74
INS24

CON61
PEP74
INS19

CON62
PEP74
INS12

CON63
PEP10
INS3

CON64
PEP74
INS18

CON65
PEP74
INS17

CON66
PEP74
INS14

CON67
PEP69
INS15

CON68
PEP74
INS15

CON69
PEP74
INS25

CON70
PEP74
INS20

CON71
PEP29
INS2

CON72
PEP30
INS2

CON73
PEP31
INS2

CON74
PEP32
INS2

CON75
PEP34
INS2

CON76
PEP35
INS2

CON77
PEP37
INS2

CON78
PEP74
INS21

CON79
PEP74
INS1

CON80
PEP1
INS3

CON81
PEP6
INS3

CON82
PEP29
INS3

CON83
PEP33
INS2

CON84
PEP36
INS2

CON85
PEP38
INS2

CON86
PEP39
INS2

CON87
PEP40
INS2

CON88
PEP43
INS2

CON89
PEP41
INS2

CON90
PEP42
INS2

CON91
PEP75
INS2

CON92
PEP74
INS25

CON93
PEP1
INS3

CON94
PEP6
INS3

CON95
PEP74
INS25

CON96
PEP74
INS26

CON97
PEP74
INS27

CON98
PEP74
INS28

CON99
PEP74
INS29

CON100
PEP74
INS30

CON101
PEP74
INS31

CON102
PEP76
INS2

CON103
PEP77
INS2

CON104
PEP74
INS19

CON105
PEP36
INS19

CON106
PEP78
INS0

CON107
PEP101
INS32

CON108
PEP79
INS32

CON109
PEP80
INS32

CON110
PEP81
INS32

CON111
PEP82
INS32

CON112
PEP83
INS32

CON113
PEP84
INS32

CON114
PEP85
INS32

CON115
PEP86
INS32

CON116
PEP87
INS32

CON117
PEP88
INS32

CON118
PEP89
INS32

CON119
PEP90
INS32

CON120
PEP91
INS32

CON121
PEP92
INS32

CON122
PEP93
INS32

CON123
PEP94
INS32

CON124
PEP95
INS32

CON125
PEP96
INS32

CON126
PEP97
INS32

CON127
PEP98
INS32

CON128
PEP99
INS32

CON129
PEP100
INS32

CON130
PEP101
INS32

CON131
PEP102
INS32

CON132
PEP103
INS32

CON133
PEP104
INS32

CON134
PEP105
INS32

CON135
PEP106
INS32

CON136
PEP107
INS32

CON137
PEP108
INS32

CON138
PEP109
INS32

CON139
PEP110
INS32

CON140
PEP111
INS32

CON141
PEP112
INS32

CON142
PEP113
INS32

CON143
PEP114
INS32

CON144
PEP115
INS32

CON145
PEP116
INS32

CON146
PEP117
INS32

CON147
PEP118
INS32

CON148
PEP119
INS32

CON149
PEP120
INS32

CON150
PEP121
INS32

CON151
PEP122
INS32

CON152
PEP123
INS32

CON153
PEP124
INS32

CON154
PEP125
INS32

CON155
PEP126
INS32

CON156
PEP127
INS32

CON157
PEP128
INS32

CON158
PEP129
INS32

CON159
PEP130
INS32

CON160
PEP131
INS32

CON161
PEP132
INS32

The conjugates are shown in FIG. 2A, FIG. 2B, and FIG. 2C which show various exemplary insulin-incretin conjugates in which the Norleucine (Nle) amino acid of particular incretins is conjugated to the epsilon amino group of Lysine (Lys) at position B29 of the B-chain peptide; FIG. 3, which shows various exemplary insulin-incretin conjugates in which the Ne amino acid of particular incretins is conjugated to the amino group of the Glycine (Gly) at position A1 of the A-chain peptide; FIG. 4A, FIG. 4B, FIG. 4C, FIG. 4D, FIG. 4E, FIG. 4F, FIG. 4G, FIG. 4H, FIG. 4I, FIG. 4J, FIG. 4K, FIG. 4L, FIG. 4M, FIG. 4N, FIG. 4O, and FIG. 4P, which show exemplary insulin-incretin conjugates in which the Ne amino acid of particular incretins is conjugated to the amino group of the Phenylalanine (Phe) at position B1 of the B-chain peptide; FIG. 5, which shows an exemplary insulin-incretin conjugate in which the Nle amino acid of PEP74* is conjugated to the amino group of the Phe at position B1 of the B-chain peptide; FIG. 6A, FIG. 6B, FIG. 6C, and FIG. 6D show exemplary insulin-incretin conjugates in which the epsilon amino group of Lys of the incretin is conjugated to the amino group of the Phe at position B1 of the B-chain peptide; FIG. 9A, FIG. 9B, FIG. 9C, FIG. 9D, FIG. 9E, FIG. 9F, FIG. 9G, FIG. 9H, FIG. 9I, FIG. 9J, FIG. 9K, and FIG. 9L, which show exemplary insulin-incretin conjugates in which the Norleucine (Nle) amino acid of the incretin is conjugated to the amino group of the Phe at position B1 of the B-chain peptide; FIG. 10A, FIG. 10B, FIG. 10C, FIG. 10D, FIG. 10E, FIG. 10F, and FIG. 10G, which show exemplary insulin-incretin conjugates in which the epsilon amino group of Lys of the incretin is conjugated to the amino group of the Phenylalanine (Phe) at position B1 of the B-chain peptide; and FIG. 11, which shows exemplary insulin-incretin conjugates CON106 and CON107. The “*” shown for various peptides indicates that the incretin has the amino acid sequence and structure of the indicated incretin but wherein the azide group of the linker has formed a 1,2-disubstituted 1,2,3-triazole with the alkyne group on the insulin.

Example 25

Activity of the incretin peptides or the conjugates at the Glucagon receptor (GCGR) and GLP-1 receptor (GLP1R) may be measured in a cAMP activity assay as follows.

Peptides are dissolved in 100% DMSO and serially diluted to generate 10 point titrations. The peptide solutions are then transferred into 384-well assay plates (150 nL/well). Assay ready frozen cells expressing human GLP1R or human GCGR are suspended in growth media consisting of DMEM medium (GIBCO), 10% FBS (GIBCO), 1×NEAA(GIBCO), 1×P/S (GIBCO), 10 μg/mL Blasticidin (GIBCO) and 200 μg/mL Hygromycin (GIBCO). Cells are then diluted in assay buffer consisting of PBS (GIBCO), 7.5% BSA (Perkin Elmer), 100 μM RO 20-1724 (Sigma), with or without 20% human serum (MP Biomedical). The cell suspensions (15 μL) are then added to the assay plates containing the peptide solutions (30,000 cells/well for human GCGR; 10,000 cells/well for human GLP1R). The cells are incubated for one hour at room temperature in the dark.

Production of cAMP may be determined using HitHunter™ cAMPXS kits (DiscoverX) following the manufacturer's protocol. The plates are incubated for overnight at room temperature in the dark. Luminescence may be measured using an EnVision Multilabel plate reader (Perkin Elmer). Native GLP-1 and Glucagon (Bachem) may be used as control peptides. EC₅₀values may be calculated using uses a 4 parameter logistic fit based on the Levenberg-Marquardt algorithm. The results for several of the peptides are shown in Table 5.

TABLE 5

Peptide
Azide
hGCGR_EC₅₀
hGLP1R EC₅₀
GCGR/GLP1R

Name
position
(nM)
(nM)
ratio

PEP1
21
0.01
0.03
0.5

PEP2
24
0.11
0.03
3.7

PEP3
24
0.07
0.02
4.6

PEP4
24
0.41
0.48
0.9

PEP5
30
0.24
1.04
0.2

PEP6
30
0.07
0.17
0.4

PEP7
24
0.06
0.38
0.2

PEP8
30
0.77
0.31
2.5

PEP9
24
0.45
0.15
3.1

PEP10
24
0.02
0.03
0.7

PEP11
24
0.03
0.06
0.4

PEP12
24
0.02
0.07
0.3

PEP13
24
0.04
0.10
0.4

PEP14
24
0.05
0.07
0.8

PEP15
24
0.02
0.03
0.7

PEP16
21
0.05
0.06
0.8

PEP17
21
0.06
0.05
1.2

PEP18
31
0.21
0.03
6.7

PEP19
31
0.47
0.34
1.4

PEP20
31
0.10
0.05
2.0

PEP21
31
0.08
0.07
1.1

PEP22
24
0.13
0.07
1.9

PEP25
24
0.04
0.05
0.8

PEP26
20
0.12
0.12
1.0

PEP27
21
0.39
0.06
6.5

PEP28
31
0.17
0.16
1.1

PEP29
24
3.26
3.28
1.0

PEP30
24
2.27
0.50
4.5

PEP31
24
4.24
1.38
3.1

PEP32
24
0.06
0.04
1.5

PEP34
24
0.05
0.05
1.0

PEP35
24
0.05
0.05
1.0

PEP37
24
0.06
0.04
1.5

PEP68
24
2.7
0.07
38.6

PEP69
24
0.31
0.16
1.9

PEP70
20
3.47
0.04
86.8

PEP71
20
0.12
0.06
2.0

PEP72
32
3.90
0.04
97.5

PEP73
30
4.57
7.58
0.6

PEP74
24
0.02
0.05
0.4

PEP75
24
>5
0.07
>72

Example 26

The conjugate binding or affinity to the insulin receptor may be performed using the following Insulin Receptor Binding Assays.

Two competition binding assays may be utilized to determine affinity for the human insulin receptor type B (IR(B)) against the endogenous ligand, insulin, labeled with ¹²⁵[I].

Method 1 IR binding assay is a whole cell binding method using CHO cells overexpressing human IR(B). The cells are grown in F12 media containing 10% FBS and antibiotics (G418, Penicillin/Strepavidin), plated at 40,000 cells/well in a 96-well tissue culture plate for at least eight hours. The cells are then serum starved by switching to DMEM media containing 1% BSA (insulin-free) overnight. The cells are washed twice with chilled DMEM media containing 1% BSA (insulin-free) followed by the addition of conjugate at appropriate concentration in 90 μL of the same media. The cells are incubated on ice for 60 minutes. The ¹²⁵[I]-insulin (10 μL) is added at 0.015 nM final concentration and incubated on ice for four hours. The cells are then gently washed three times with chilled media and lysed with 30 μL of Cell Signaling lysis buffer (cat #9803) with shaking for 10 minutes at room temperature. The lysate is added to scintillation liquid and counted to determine ¹²⁵[I]-insulin binding to IR and the titration effects of the conjugate on this interaction.

Method 2 IR binding assay is run in a scintillation proximity assay (SPA) in 384-well format using cell membranes prepared from CHO cells overexpressing human IR(B) grown in F12 media containing 10% FBS and antibiotics (G418, Penicillin/Strepavidin). Cell membranes are prepared in 50 mM Tris buffer, pH 7.8 containing 5 mM MgCl₂. The assay buffer contains 50 mM Tris buffer, pH 7.5, 150 mM NaCl, 1 mM CaCl₂, 5 mM MgCl₂, 0.1% BSA and protease inhibitors (Complete-Mini-Roche). Cell membranes are added to WGA PVT PEI SPA beads (5 mg/mL final concentration) followed by addition of conjugate at appropriate concentrations. After 5-15 min incubation at room temperature, ¹²⁵[I]-insulin is added at 0.015 nM final concentration for a final total volume of 50 μL. The mixture is then incubated with shaking at room temperature for 1 to 12 hours followed by scintillation counting to determine ¹²⁵[I]-insulin binding to IR and the titration effects of conjugate on this interaction.

Example 27

Conjugate agonist activity at the insulin receptor may be performed using the following Insulin Receptor Phosphorylation Assays.

Insulin receptor activation can be assessed by measuring phosphorylation of the Akt protein, a key step in the insulin receptor signaling cascade. CHO cell lines overexpressing either human, minipig or dog IR are utilized in an HTRF sandwich ELISA assay kit (Cisbio “Phospho-AKT(Ser473) and Phospho-AKT(Thr308) Cellular Assay Kits”). Cells are grown in F12 media supplemented with 10% FBS, 400 ug/ml G418 and 10 mM HEPES. Prior to assay, the cells are incubated in serum free media for 2 to 4 hours. Alternatively, the cells may be frozen and aliquoted ahead of time in media containing 20% DMSO and used in the assay upon thawing, spin down and re-suspension.

Cells are plated at 10,000 cells per well in 20 ul of the serum free F12 media in 384-well plates. Humulin and glargine controls were run on each plate of test compounds. The titrated compounds are added to the cells (2 μL per well, final concentrations=1000 nM titrated down to 0.512 μM in 1:5 fold dilutions) and incubated at 37° C. for 30 minutes. The cells are lysed with 8 μL of the prepared lysis buffer provided in the CisBio kit and incubated at 25° C. for one hour. The diluted antibody reagents (anti-AKT-d2 and anti-pAKT-Eu3/cryptate) are prepared according to the kit instructions and then 10 μL is added to each well of cell lysate followed by incubation at 25° C. for 3.5 to 5 hours. The plate may be read by in an Envision plate reader (Excitation=320 nm; Emission=665 nm) to determine the IR pAkt agonist activity with regard to both potency and maximum response for each compound. Alternatively, the compounds may be tested in the same manner in the presence of 1.6 nM of Humulin to determine how each compound was able to compete against the full agonist activity of insulin.

Example 28

Table 6 shows the incretin and insulin agonist activity of the various insulin incretin conjugates disclosed herein. Table 7 shows the incretin agonist activity or insulin agonist activity of several control molecules. Control molecule PEP76 has the amino acid sequence HsQGTFTSDK(γEγEC₁₆)SKYLDERAAQDFVQWLLDT-NH₂(SEQ ID NO:110) and corresponds to the amino acid sequence of PEP74 except that PEP76 has the amino acid Gln (Q) at position 24 instead of Nle(εN₃) as in PEP74.

TABLE 6

Incretin Receptor Assay

(cAMP) EC₅₀
Insulin Receptor
Insulin Receptor

(nM)
Binding Assay EC₅₀
pAK Assay EC₅₀

GCGR
GLP1R
Ratio
(nM)
(nM)

Conjugate
(Human)
(Human)
GCGR/GLP1R
Human
Minipig
Human
Minipig

CON1
20
1.42
14.1
1445
2500
4.325
3.276

CON2
20
3.35
6.0
2.347
4.339
0.185
0.352

CON3
20
4.93
4.1
2500
2500
24.6
27.98

CON4
2.82
6.1
0.5
1.1
6
0.206
0.35

CON5
5
5
1.0
22.5
41.9
0.9
0.74

CON6
1.55
3.67
0.4
61.13
191.7
4.353
3.276

CON7
20
2.72
7.4
372.5
2500
9.6
3.276

CON8
20
5
4.0
2500
2500
21.1
21.3

CON9
20
5
4.0
3.964
7.5
0.312
0.63

CON10
2.56
2.39
1.1
142.7
451
13.17
13.86

CON11
3.34
5
0.7
3.21
8.988
0.292
0.673

CON12
5
5
1.0
233.6
234.6
9.97
6.22

CON13
20
5
4.0
15.11
24.36
0.26
0.65

CON14
20
20
1.0
1.89
3.43
0.02
0.07

CON15
20
20
1.0
25.59
13.71
0.53
0.37

CON16
0.06
0.17
0.4
19.53
13.67
0.37
0.63

CON17
0.1
0.06
1.7
149.9
169.9
33
16.2

CON19
5
20
0.3
0.77
2.15
0.05
0.13

CON20
5
5
1.0
2.76
3.93
0.05
0.09

CON21
0.09
0.08
1.1
12.68
26.58
0.49
0.96

CON22
0.06
0.04
1.5
12
29.84
0.11
0.19

CON23
0.12
0.13
0.9
10.28
23.59
0.08
0.18

CON24
0.07
0.09
0.8
7.61
16.76
0.4
0.75

CON25
0.1
0.1
1.0
20.26
28.66
0.08
0.19

CON26
0.08
0.18
0.4

0.3
0.83

CON27
0.08
0.11
0.7

0.07
0.27

CON28
0.32
0.23
1.4

0.25
0.74

CON29
1.47
0.06
24.5

0.61
0.95

CON30
2.89
0.07
41.3

5.29
17.24

CON31
2.02
4.42
0.5

0.62
2.04

CON32
1.2
6.05
0.2

0.41
2.54

CON33
0.25
0.42
0.6

0.21
0.97

CON34
0.42
1.32
0.3

0.72
1.65

CON35
2.2
1.88
1.2

0.33
1.35

CON36
16.47
3.08
5.3

0.12
0.35

CON37
0.34
0.08
4.3

0.14
0.5

CON38
0.34
3.32
0.1

0.63
2.22

CON39
0.08
0.34
0.2

2.02
4.55

CON40
0.13
0.38
0.3

6.82
12.58

CON41
0.18
0.13
1.4

0.58
1.28

CON42
0.11
0.08
1.4

0.15
0.32

CON43
0.31
0.11
2.8

0.72
1.71

CON44
0.21
0.1
2.1

0.79
1.81

CON45
2.42
0.44
5.5

0.69
1.49

CON46
0.76
0.08
9.5

0.18
0.53

CON47
0.72
0.07
10.3

0.49
1.25

CON48
0.53
0.05
10.6

0.33
0.66

CON49
0.65
0.11
5.9

0.47
0.72

CON50
0.53
2.57
0.2

0.08
0.2

CON51
1.42
2.83
0.5

0.11
0.3

CON52
0.43
2.08
0.2

0.15
0.42

CON53
4.95
1.74
2.8

0.94
2.84

CON55
0.16
0.13
1.2

0.59
1.42

CON56
0.12
0.05
2.4

0.33
0.59

CON57
0.23
0.09
2.6

0.29
0.5

CON58
19.8
19.8
1.0

1.51
2.82

CON59
19.8
19.8
1.0

3.18
4.49

CON60
1.23
1.08
1.2

43.03
1000

CON61
0.25
0.1
2.5

6.47
6.32

CON62
0.06
0.02
3.0

0.25
0.63

CON63
0.16
0.05
3.2

0.05
0.28

CON64
0.26
0.16
1.6

9.8
7.46

CON65
0.23
0.08
2.9

1000
1000

CON66
0.24
0.1
2.4

0.17
0.3

CON67
4.95
4.95
1.0

0.18
0.29

CON68
0.15
0.09
1.7

2.43
4.5

CON69
0.22
0.17
1.3

1000
117.8

CON70
0.0585
0.035
1.7

3.28
3.28

CON71
19.8
19.8
1.0

15.01
22.47

CON72
19.8
11.95
1.7

47.6
15.75

CON73
19.8
8.69
2.3

14.6
10.02

CON74
0.75
1.53
0.5

0.27
0.28

CON75
0.39
2.32
0.2

0.96
1.53

CON76
0.15
3.05
0.0

0.55
1.05

CON77
0.46
2.17
0.2

1.27
1.01

CON78
0.18
0.11
1.6

1.65
1.27

CON79
0.13
0.14
0.9

51.23
27.5

CON80
0.24
0.25
1.0

0.25
0.69

CON81
0.22
0.46
0.5

0.21
0.58

CON82
19.8
19.8
1.0

5.13
9.73

CON83
0.57
0.86
0.7

6.1
4.5

CON84
0.16
0.3
0.5

0.05
0.09

CON85
0.08
0.68
0.1

0.07
0.19

CON86
2.55
0.26
9.8

0.71
1.55

CON87
0.51
1.73
0.3

0.51
1.19

CON88
0.37
2.13
0.2

0.61
1.21

CON89
0.55
0.15
3.7

0.27
0.61

CON90
0.31
0.19
1.6

0.14
0.4

CON91
19.8
0.21
94.3

0.15
0.38

CON92
0.18
0.18
1.01

0.23

CON93
0.22
0.46
0.48

0.205

CON94
0.56
15.24
0.036

2.94

CON95
0.94
2.62
0.36

1.4

CON96
1.21
2.78
0.43

8.67

CON97
2.51
4.04
0.62

4.86

CON98
0.63
1.11
0.56

17.29

CON99
0.08
0.16
0.48

0.96

CON101
19.8
1.19
8.0916.5

0.48

CON102
1.81
0.22
7.74

0.569

CON103
19.8
0.31
62.79

0.073

CON104
0.08
0.56
0.14

2.57

CON105
0.18
1.62
0.11

13.92

CON106
0.21
1.17
0.17

2.16

CON107
0.08
6.02
0.013

0.47

CON108
0.57
8.62
0.066

6.102

CON109
0.16
0.30
0.53

0.046

CON110
0.09
0.68
0.13

0.070

CON111
2.55
0.26
9.7

0.70

CON112
0.51
1.73
0.29

0.51

CON113
0.37
2.126
0.17

0.61

CON114
0.31
0.19
1.63

0.13

CON115
0.55
0.15
3.55

0.27

CON116
19.8
0.20
96.39

0.15

CON117
0.17
0.28
0.60

0.16

CON118
0.22
0.37
0.59

0.36

CON119
0.68
0.26
2.72

0.45

CON120
0.16
0.079
1.42

0.37

CON121
2.5
0.28
9.0

1.48

CON122
2.42
0.46
5.28

0.92

CON123
14.07
1.1
12.72

0.44

CON124
0.22
6.18
0.035

0.3454

CON125
1.71
1.15
1.48

0.28

CON126
0.56
0.59
0.93

0.438

CON127
1.27
19.8
0.064

0.93

CON128
0.15
0.20
0.72

0.197

CON129
1.54
1.75
0.878

1.44

CON130
0.21
19.8
0.01

0.137

CON131
0.22
1.73
0.128

0.51

CON132
1.19
1.66
0.72

0.36

CON133
0.64
0.47
1.37

0.42

CON134
0.25
0.05
4.54

0.25

CON135
0.48
0.71
0.66

0.14

CON136
0.7
0.50
1.39

2.09

CON137
1.04
0.16
6.62

0.063

CON138
0.95
0.72
1.32

0.12

CON139
0.2
19.8
0.01

0.47

CON140
0.34
0.21
1.61

0.066

CON141
0.96
0.72
4.57

0.12

CON142
0.68
0.74
0.91

0.730

CON143
0.33
2.77
0.11

1.04

CON144
0.04
1.95
0.02

27.9

CON145
0.43
0.20
2.15

0.10

CON146
0.42
4.95
0.08

0.20

CON147
0.3555
0.59
0.59

0.63

CON148
0.29
0.05
5.8

0.42

CON149
0.22
0.07
3.14

0.6

CON150
0.17
0.09
1.88

1.36

CON151
0.27
0.16
1.68

0.6

CON152
0.37
2.89
0.13

0.15

CON153
3.47
2.68
1.29

0.18

CON154
1.73
0.46
2.82

0.3

CON155
0.32
1.58
0.20

0.14

CON156
>20
>20

17.39

CON157
>20
>20

9.45

CON158
>5
>5

9.45

CON159
>20
>5

8.52

CON160
1.87
0.05
37.4

1.12

CON161
5.99
0.12
49.9

1.22

TABLE 7

Incretin Receptor Assay

(cAMP) EC50
Insulin Receptor
Insulin Receptor

(nM)
Binding Assay EC50
pAK Assay EC50

GCGR
GLP1R
Ratio
(nM)
(nM)

(Human)
(Human)
GCGR/GLP1R
Human
Minipig
Human
Minipig

PEP76
0.009
0.007
1.3

PEP74
0.02
0.05
0.4

RHI

0.35
0.59
0.01
0.02

IG

0.57
0.77
0.01
0.01

IL

0.51
0.5

ID

9.03
8.46
0.48
0.35

RHI = Recombinant human insulin

IG = Insulin glargine

IL = Insulin levemir

ID = Insulin degludec

FIG. 7 shows that the length of the linking moiety at B1 has an effect on the ratio of glucagon (GCG) activity to GLP-1 activity.

FIG. 8 shows that the length of the linking moiety at B29 has an effect on the activity of the insulin at the insulin receptor ratio of GCG activity to GLP-1 activity.

Example 29

The following compounds were prepared following the procedure as disclosed in Example 6 in the provisional filing.

embedded image

Example 30

The insulin analogs shown below were prepared using the procedure described for INS7 (Example 14)

1. N^αB1-propargyl-C₅-Lys(γE-C₁₆)-PEG₂₄-RHI (INS25)

embedded image

2. N^αB1-propargyl-C5-Lys(γE-C₁₂)-PEG₁₂-RHI (INS26)

embedded image

3. N^αB1-propargyl-C5-Lys(γE-C₁₆)-PEG₄-RHI (INS27)

embedded image

4. N^αB1-propargyl-C5-Lys(γE-C₁₈—OH)-PEG₁₂-RHI (INS28)

embedded image

Example 31

Synthesis of N^εB28-propargyl-PEG₄Lispro (INS29)

embedded image

was as follows.

In a 20 mL vial, insulin Lispro (100 mg, 0.017 mmol) is dissolved in DMSO (1 mL) and aged at RT until homogeneous. 1,1,3,3-tetramethylguanidine (43 μl, 0.35 mmol) is added and followed by slow addition of alkyne-PEG₄-NHS (2,5-dioxopyrrolidin-1-yl 4,7,10,13-tetraoxahexadec-15-ynoate, 6.8 mg, 0.019 mmol) solution in DMSO (0.5 mL) via syringe pump over 30 min. The reaction is stirred at RT for one hour. The mixture is added dropwise to IPAc (20 mL) to precipitate out the product. The solids are filtered and dried under nitrogen gas and vacuum for 30 minutes. The solids are dissolved in 15 mL mix solvent (80% water, 20% ACN, pH=3.0), adjusted pH to 3. The residue is purified by RP-HPLC column, using the separation condition (28-35%) 0.05% TFA in AcCN/H₂O on Kromasil 100-10-C8 from AkzoNobel, 100 A and 10 μM 50×250 mm column; FR=85 mL/minute, ramp 25 minutes, wavelength=210 nm. The fractions are collected and lyophilized to give N^εB28-propargyl-PEG₄Lispro.

Example 32

Synthesis of N^εB1-propargyl-PEG₄Lispro (INS30)

embedded image

followed the procedure disclosed for INS3 (Example 13).

Example 33

Synthesis of N^εB29-propargyl-PEG₄Aspart (INS31)

embedded image

followed the procedure disclosed for INS17 (Example 16).

Example 34

Synthesis of CON106 in which a C8 hydrocarbon linker links the lysine at position 24 of PEP78 to the B1 amino group of RHI (INS0) was as follows.

embedded image

Step 1: Synthesis of PEP78 with Dde protecting groups at the N-terminus amino group and the lysine at position 12 followed the general procedure set out in Example 1.

Step 2: To a solution of bis(2,5-dioxopyrrolidin-1-yl) octanedioate (35.0 mg, 0.095 mmol) and TEA (0.026 ml, 0.190 mmol) in DMSO (2 ml) was added Pep7290-Dde (20 mg, 4.75 μmol) in DMSO (1 ml) via syringe pump over 1 h. The reaction was quenched after 2 h with 2 ml mixed solvent (ACN/water 20:80, pH 3) and adjusted to pH 2.5. The residue is purified by RP-HPLC, using the separation condition (50-70%) 0.05% TFA in ACN/H₂O on Kromasil 100-10-C8 from AkzoNobel, 100 A and 10 μM 50×250 mm column; FR=85 mL/minute, ramp 25 minutes, wavelength=210 nm. The desired fractions are collected and lyophilized to give the desired product. m/z 1489.5 [M+3]/3.

Step 3: A1,B29-bis-Boc RHI (34.4 mg, 5.73 μmol) was dissolved in DMF 0.5 ml in a 10 ml vail, to the solution was added Et₃N (4 μl, 0.029 mmol). The product from step 1 (12.8 mg, 2.87 μmol) in DMSO (400 μl and rinsed with 200 μl) was added over 30 min. The reaction mixture was stirred at rt overnight and used in the next step without purification. m/z: 1727.4 [M+6]/6.

Step 4: To the DMSO solution of crude product in step 3 was added 6 μl of hydrazine in DMF (36% in DMF). After stirring for one hour, the reaction mixture is dropwise added to a stirred 10 mL of IPAc to precipitate the product. The white solids are filtered, washed with IPAc and dried under N₂and vacuum for one hour. m/z: 1672.2 [M+6]/6.

Step 5: TFA (0.5 mL, 6.5 mmol) is added to the above crude material (28.8 mg, 2.87 μmol) and the reaction is stirred and sonicated until solids fully dissolved (about 30 minutes). The reaction mixture is dropwise added to IPAc (10 mL) and the precipitated solids are filtered and dried under N₂and vacuum. The crude material is purified by RP-HPLC, using the separation condition (32-46%) 0.05% TFA in ACN/H₂O on Kromasil 100-10-C8 from AkzoNobel, 100 A and 10 μM 50×250 mm column; FR=85 mL/minute, ramp 25 minutes, wavelength=210 nm. The desired fractions are collected and lyophilized to give the hydrocarbon linked conjugate CON106. m/z: 1966.4 [M+5]/5.

Example 35

Synthesis of B1 azido RHI (INS32) was as follows.

embedded image

A1,B29-Bis Boc Insulin (100 mg, 0.017 mmol), sodium bicarbonate (5.6 mg, 0.067 mmol), copper(II) sulfate (0.53 mg, 3.33 μmol) was dissolved in water (0.8 mL) and MeOH (0.2 mL) was added 1H-imidazole-1-sulfonyl azide hydrochloride (5.6 mg, 0.027 mmol), maintained pH 8-9 by adding aq. sat. NaHCO₃solution and stirred at room temperature overnight. Lyophilized the crude material and added TFA (2 mL, 0.017 mmol) for deprotection to give INS32 in which the N-terminal amino group has been converted to an azido group.

INS32 was conjugated to PEP101 following procedures disclosed herein to produce CON107 having the structure

embedded image

While the present invention is described herein with reference to illustrated embodiments, it should be understood that the invention is not limited hereto. Those having ordinary skill in the art and access to the teachings herein will recognize additional modifications and embodiments within the scope thereof. Therefore, the present invention is limited only by the claims attached herein.

INSULIN-INCRETIN CONJUGATES

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

CROSS REFERENCE TO RELATED APPLICATIONS